

FUNCTIONALLY GRADED PLGA-NANO APATITE-LAURIC ACID
BIOCOMPOSITE MEMBRANE FOR POTENTIAL
CLINICAL APPLICATIONS

JAMUNA THEVI A/P KALITHEERTHA THEVAR

A thesis submitted in fulfilment of the
requirements for the award of the degree of
Doctor of Philosophy (Biomedical Engineering)

Faculty of Biosciences and Medical Engineering
Universiti Teknologi Malaysia

MAY 2017

To my dearest mother.....

Mrs. Jannanayagam

For being a mentor, friend and pillar of strength

ACKNOWLEDGEMENTS

I would like to express my sincere gratitude to my main supervisor, Prof. Dato' Ir. Dr. Mohammed Rafiq Abdul Kadir for his precious time, patience, encouragement and expertise rendered throughout this project. His exquisite attention to detail and demand for excellence has always encouraged me to widen my research perspectives and writing of this thesis.

Besides my main supervisor, I sincerely appreciate and thank the efforts of my co-supervisor, Dr. Nik Ahmad Nizam Nik Malek for his insightful comments and encouragement for the writing of this thesis.

My sincere appreciation is also extended to Dr. Hendra Hermawan (currently at Université Laval, Canada) who provided the opportunity to join his research team at Universiti Teknologi Malaysia. Without his precious support and encouragement, it would not be possible to conduct this research or to publish the related works.

Being the employee of SIRIM Berhad, I deeply appreciate the supports provided by my employer to pursue an advanced degree, particularly for sponsoring my studies continuously throughout the years. Also, an opportunity to broaden my knowledge was made possible through the supports provided by Dr. Mohd Radzi Mohd Toff (General Manager) and Dr. Kartini Noorsal (Head of Biomedical Materials Section) who allowed me to use the research and laboratory facilities at Advanced Materials Research Centre (AMREC), SIRIM Berhad for the purpose of fulfilling PhD degree requirements.

I am also grateful to Prof. Dr. T.S Sampath Kumar (Indian Institute of Technology Madras, India) for sharing his knowledge on fundamental science and

technical aspects of research instruments utilised in this project, during his visit to AMREC, SIRIM Berhad.

I am greatly indebted to Ministry of Science, Technology and Innovation (MOSTI), Malaysia for funding this research project through the Science Fund (03-03-02-SF0280).

Last but not the least, my appreciation from the bottom of my heart is to my family members, friends and colleagues who have invariably supported me all the time despite it was a down fall or joyous moments while going through this important stage of my life.

ABSTRACT

Bone healing is a challenge in orthopaedics and dentistry. An occlusive membrane is used for the reconstruction of bone defects in guided bone regeneration (GBR) technique. Infection is the major cause for GBR membrane failure in which multiple antibiotics have been used to prevent bacterial colonisation in regenerative clinical practice. An anti-infective membrane with alternative antimicrobial agent to substitute antibiotics is paramount to overcome the incidence of bacterial resistance and side-effects. In this study, a composite membrane was developed by incorporating lauric acid (LA), a naturally derived antimicrobial substance. Poly(lactic-co-glycolic acid) (PLGA) based composite membrane was successfully fabricated using a combination of solvent casting-thermally induced phase separation (TIPS)-solvent leaching technique. The triple-layered membrane structure was attained via solvent casting of the composite solutions which then immediately phase separated by freezing at $-18\pm 1^\circ\text{C}$ for 24 h. Then, the solvent in phase separated membrane was removed by immersing in precooled water at $3\pm 1^\circ\text{C}$ for 26 h, after which the membrane was air dried at 25°C for 3 days. The triple-layered construct of the PLGA composite membrane was developed with a gradient structure of LA and non-stoichiometric nanoapatite (NAP), to deliver the antimicrobial and osteoconductive properties, respectively. The surface morphology and phase composition of the membrane were examined using scanning electron microscopy (SEM) and X-ray diffraction (XRD), respectively. The resulting graded membrane consisted of small pore size layer-1 containing 10wt% NAP + 1-3wt% LA, an intermediate labyrinth layer-2 with 20-50wt% NAP + 1wt% LA, and a large pore size layer-3 containing 30-100wt% NAP without LA. The existence of chemical interaction between PLGA, NAP and LA was identified using Fourier transform infrared spectrophotometry (FTIR) analysis. The synergistic effects of 10-30wt% NAP and 1wt% LA in dry membranes demonstrated higher tensile strength (0.61 ± 0.17 MPa) and elastic modulus (23.15 ± 6.19 MPa). However, a more pliable behavior with a decrease in elastic modulus (12.50 ± 4.32 MPa) was observed in 3wt% LA added membrane compared to the pure PLGA (20.17 ± 2.21 MPa). The addition of LA resulted in a plasticizing effect at 3wt% due to weak intermolecular interactions in PLGA chains, caused by LA (-OH) and PLGA (C-O) bondings. These results were corroborated by the FTIR peak shift ($1-3\text{ cm}^{-1}$) and glass transition temperature (T_g) reduction as detected using differential scanning calorimeter (DSC). The composite membrane retained its structural integrity with only 22% weight loss after incubation for 24 weeks in phosphate buffered saline (PBS), which indicates its potential use as a physical barrier. The 1-3wt% LA loaded composite membranes had good cell viability toward mouse fibroblasts and showed increased bacterial reduction with increased LA loadings against *S. aureus*. These results demonstrate the potential of LA loaded biocomposite membrane to provide anti-infective surfaces, useful in clinical applications.

ABSTRAK

Penyembuhan tulang adalah satu cabaran dalam bidang ortopedik dan pergigian. Pertumbuhan semula tulang berpandukan (GBR) telah digunakan untuk pembinaan semula kecacatan tulang dengan menggunakan membran penghalang. Jangkitan adalah punca utama kegagalan membran tersebut di mana beberapa antibiotic telah digunakan untuk menghalang pertumbuhan bacteria dalam amalan klinikal. Agen antibakteria alternatif adalah perlu untuk mengatasi kesan sampingan dan rintangan bacteria yang dihasilkan oleh antibiotik. Dalam kajian ini, membran komposit telah dibangunkan melalui penggabungan asid laurik (LA) yang mempunyai sifat antibakteria. Membran komposit berasaskan asid poli(laktik-co-glycolic) (PLGA) telah berjaya direka dengan menggunakan gabungan teknik-teknik pelarut tuangan-pemisahan fasa haba teraruh-larut lesap pelarut. Struktur membran tiga-lapis telah dihasilkan melalui pelarut tuangan komposit yang telah melalui pemisahan fasa haba teraruh pada suhu $-18\pm 1^{\circ}\text{C}$ selama 24 jam. Kemudian, pelarut membran telah dibuang dengan merendamkannya dalam air sejuk pada suhu $3\pm 1^{\circ}\text{C}$ selama 26 jam. Setelah itu, membran telah dikeringkan di udara pada 25°C selama 3 hari. Membran komposit PLGA tiga-lapis ini telah difabrikasi dengan struktur kecerunan melalui penambahan LA dan apatitnano bukan stoikiometrik (NAp) yang memainkan peranan sebagai antimikrob dan penggalak pertumbuhan tulang. Morfologi permukaan dan fasa komposisi membran telah diperiksa dengan menggunakan mikroskopi elektron imbasan (SEM) dan pembelauan sinar-X (XRD). Membran ini terdiri daripada lapisan-1 dengan saiz liang kecil yang mengandungi 10% berat NAp + 1-3% berat LA, lapisan-2 sebagai lapisan perantara dengan 20-50% berat NAp + 1% berat LA dan akhirnya lapisan-3 dengan saiz liang besar yang mengandungi 30-100% berat NAp tanpa LA. Kewujudan interaksi kimia antara PLGA, NAp dan LA telah dikenalpasti dengan menggunakan analisis spektrometer inframerah (FTIR). Kesan sinergi diantara 10-30% berat NAp dan 1% berat LA dalam membran komposit kering menunjukkan kekuatan tegangan (0.61 ± 0.17 MPa) dan modulus elastik (23.15 ± 6.19 MPa) yang tinggi manakala membran mudah bentuk diperolehi dengan penurunan dalam modulus elastik (12.50 ± 4.32 MPa) selepas penambahan 3% berat LA berbanding membran PLGA tulen (20.17 ± 2.21 MPa). Penambahan 3% berat LA mengakibatkan kesan liat disebabkan interaksi lemah dalam rangkaian PLGA melalui ikatan LA (-OH) dan PLGA (-CO). Ini telah dibuktikan melalui perubahan puncak FTIR ($1-3\text{ cm}^{-1}$), dan juga penurunan suhu peralihan kaca (T_g) yang dikesan melalui kalorimeter pengimbas kebedaan (DSC). Membran komposit mengekalkan struktur integriti dengan penurunan berat sebanyak 22% selepas rendaman selama 24 minggu di dalam PBS dimana ianya mempunyai potensi sebagai penghalang fizikal. Membran komposit yang mengandungi 1-3% berat LA menunjukkan pertumbuhan sel-sel fibroblas tikus dan juga pengurangan bacteria *S. aureus* dengan peningkatan kandungan LA. Keputusan ini menunjukkan potensi membran komposit yang mengandungi LA sebagai membran anti-jangkitan untuk kegunaan dalam aplikasi klinikal.

TABLE OF CONTENTS

CHAPTER	TITLE	PAGE
	DECLARATION	ii
	DEDICATION	iii
	ACKNOWLEDGEMENTS	iv
	ABSTRACT	vi
	ABSTRAK	vii
	TABLE OF CONTENTS	viii
	LIST OF TABLES	xvii
	LIST OF FIGURES	xx
	LIST OF SYMBOLS	xxxiii
	LIST OF ABBREVIATIONS	xxxiv
	LIST OF APPENDICES	xxxvii
1	INTRODUCTION	1
	1.1 Background	1
	1.2 Problem statements	4
	1.3 Objectives of the study	5
	1.4 Research hypothesis	6
	1.5 Scope of the study	7
	1.6 Significance of the study	8
	1.7 Thesis outline	8
2	LITERATURE REVIEW	12
	2.1 Introduction	12
	2.2 Bone damage and tissue reconstruction	13

2.3	Alveolar bone loss and treatment modalities	14
2.4	Principles of guided bone regeneration	15
2.5	Design criteria for GBR membrane	16
2.5.1	Space-making properties	17
2.5.2	Cell-occlusiveness	17
2.5.3	Biocompatibility	18
2.5.4	Tissue integration	18
2.5.5	Clinical manageability	18
2.6	Commercial GBR barrier membranes for clinical applications	18
2.6.1	Non-resorbable membranes	19
2.6.2	Natural bioresorbable membranes	21
2.6.3	Synthetic bioresorbable membranes	22
2.7	Interface tissue specific functional surface layers in barrier membranes	24
2.7.1	Bioresorbable polymer-calcium phosphate composites as GBR membranes	24
2.7.1.1	Short chain saturated aliphatic polyesters	27
2.7.1.2	Multiple ions substituted non-stoichiometric nanoapatite	29
2.7.2	Antibiotics loaded GBR barrier membranes	32
2.7.2.1	Systemic versus local antibiotic treatment	34
2.7.2.2	Lauric acid as a potential antimicrobial agent for clinical use	36
2.8	Functionally graded and layered membranes for guided bone regeneration	38
2.8.1	Techniques for polymeric composite barrier membrane fabrication	40
2.8.1.1	Solvent casting	41
2.8.1.2	Thermally induced phase separation	42
2.8.1.3	Solvent leaching	43

2.9	In vitro degradation characteristics of PLGA based membranes	43
2.10	The drug release mechanism in PLGA based membranes	45
2.11	Antimicrobial efficacy studies on antibiotic loaded GBR membranes	48
2.12	Biocompatibility assessment	48
2.13	Challenges in guided bone regeneration using barrier membrane	49
3	RESEARCH METHODOLOGY	51
3.1	Introduction	51
3.2	Synthesis and characterisation of multiple ions substituted non-stoichiometric nanoapatite (NAp)	53
3.2.1	Materials for synthesis of NAp powder	54
3.2.2	Synthesis of nanoapatite powder: Effects of temperature, concentration and multiple ions substitution	54
3.2.3	Physico-chemical characterisation of the synthesised powders	59
3.2.3.1	Qualitative and quantitative analysis using X-ray diffraction (XRD)	59
3.2.3.2	Functional group characterisation using Fourier transform infrared spectrophotometry (FTIR)	61
3.2.3.3	Elemental analysis using Inductively Coupled Plasma – Atomic Emission Spectroscopy (ICP-AES)	62
3.2.3.4	Carbon, Hydrogen, Nitrogen elemental analysis	61
3.2.3.5	Image analysis by Field Emission Scanning Electron Microscopy (FESEM)	62
3.2.3.6	Image analysis by Transmission Electron Microscopy (TEM)	62

3.2.3.7	Thermal analysis using thermogravimetric and differential thermal analyser (TGA-DTA)	63
3.2.3.8	Measurement of specific surface area by Brunauer-Emmett-Teller (BET) gas adsorption method	63
3.2.3.9	Particle size analysis	63
3.2.4	In vitro cytotoxicity assay on synthesized NHA and NAp powders	64
3.2.4.1	Materials for in vitro cytotoxicity evaluation	64
3.2.4.2	Preparation of complete medium	65
3.2.4.3	Initiating cryopreserved cells	65
3.2.4.4	Subculturing adherent monolayer cells from 25 cm ² to 75 cm ² flask	66
3.2.4.5	Split suspension	67
3.2.4.6	Determining cell number with a hemocytometer and trypan blue staining	67
3.2.4.7	Preparation of powder sample extracts	68
3.2.4.8	Alamar Blue assay	68
3.3	Development of triple layered composite membrane graded with LA and NAp particles in PLGA matrix	70
3.3.1	Materials for fabrication of composite membrane	70
3.3.2	A preliminary study on fabrication and characterisation of triple-layered and graded composite membranes using solvent casting – thermally induced phase separation (TIPS) – solvent leaching techniques	71
3.3.2.1	Identification of LA and NAp presence on fabricated composite membranes	74

3.3.2.2	Reproducibility of membrane fabrication using solvent casting – TIPS – solvent leaching techniques	75
3.3.2.3	Morphological and chemical characterisation of fabricated membranes using SEM and Energy Dispersive X-ray Spectroscopy (EDS)	76
3.3.2.4	Characterisation of LA in composite membranes using FTIR	76
3.3.3	Fabrication of optimised composite membranes with various PLGA, NAp and LA contents for physical, mechanical and biological assessments	77
3.3.4	Physico-chemical and mechanical evaluation of the fabricated composite membranes	83
3.3.4.1	Morphological characterisation using VPSEM	83
3.3.4.2	Phase analysis using XRD	83
3.3.4.3	Interpretation of functional groups in composite membranes using FTIR	84
3.3.4.4	Differential scanning calorimetric (DSC) studies	84
3.3.4.5	Dry and wet mechanical strength evaluation	85
3.4	In vitro hydrolytic degradation and lauric acid release profiles of composite PLGA membranes	87
3.4.1	Materials for in vitro degradation and LA release studies	87
3.4.2	In vitro degradation of composite PLGA and pure PLGA membranes	87
3.4.3	In vitro lauric acid release studies of composite PLGA membranes	90
3.4.3.1	Extraction of LA from degradation	

	medium	91
	3.4.3.2 Loading efficiency of LA in composite PLGA membranes	92
	3.4.3.3 Derivatization of extracted lauric acid	93
	3.4.3.4 Quantification of LA using Reversed Phase High-Performance Liquid Chromatography (HPLC)	94
	3.4.4 Mathematical modeling to determine LA release mechanism	95
	3.4.4.1 Higuchi model	96
	3.4.4.2 Ritger-Peppas model	96
	3.4.4.3 First order kinetic model	97
	3.4.4.4 Zero order kinetic model	97
3.5	Quantitative in vitro antimicrobial efficacy assay on LA loaded composite membranes	98
	3.5.1 Materials for in vitro antimicrobial efficacy assay	98
	3.5.2 Bacterial culture and maintenance	98
	3.5.3 Determination of mid-log exponential growth phase of bacteria	99
	3.5.2 Antimicrobial efficacy assay	99
3.6	In vitro cytotoxicity assay on fabricated membranes	101
	3.6.1 Materials for in vitro cytotoxicity assay	101
	3.6.2 Preparation of complete medium	102
	3.6.3 Cell culture and maintenance	102
	3.6.4 Preparation of membrane sample extracts	103
	3.6.5 Alamar Blue Assay	103
4	RESULTS AND DISCUSSION	105
	4.1 Introduction	105
	4.2 Phase evaluation, physical and chemical characteristics, elemental analysis, morphology and biological evaluation of the synthesised as-prepared NHA and NAp powders	106
	4.2.1 Phase composition, crystallite size, crystallinity	

	and lattice parameters evaluation using XRD	107
4.2.2	Morphological evaluation using TEM	112
4.2.3	Physical and chemical characterisation using TGA-DTA analysis	114
4.2.4	Elemental analysis	117
4.2.5	Chemical and structural characterisation	121
4.2.6	Thermal stability	124
4.2.7	Cytotoxicity assay on as-prepared apatite powders	130
4.2.8	Summary of findings on synthesis and characterization of nanoapatite powders	132
4.3	Development and characterisation of triple-layered and graded composite PLGA membranes	133
4.3.1	A preliminary study on the design, processing conditions and effects of NAp and LA in PLGA membranes	134
4.3.1.1	The design and processing conditions of triple-layered and graded composite PLGA membranes using solvent casting-TIPS-solvent leaching technique	134
4.3.1.2	Morphological characterisation on the effects of NAp and LA addition on the formation of composite PLGA membranes	137
4.3.1.3	Identification of LA and NAp on PLGA matrices	147
4.3.1.4	Reproducible fabrication and characterisation of triple layered PLGA composite membranes with graded composition	151
4.3.2	Fabrication and, morphological, chemical and structural characterisation of the optimised composite membrane	157

4.3.2.1	Phase composition of membrane Structure	169
4.3.2.2	Chemical characteristics of PLGA-NAp-LA components in composite membrane	173
4.3.2.3	Thermal transition of phases present in composite membrane	180
4.4.	Mechanical evaluation of composite membranes in dry and wet state	184
4.4.1	Mechanical properties of composite membranes in dry state	184
4.4.2	Mechanical properties of composite membranes in wet state	190
4.5.	In vitro degradation of triple-layered and graded composite membranes containing NAp and LA in PLGA matrices	194
4.5.1	Weight loss in composite membranes	195
4.5.2	Water uptake in composite membranes	210
4.6.	In vitro quantification of loading yield, delivery profile and release mechanism of LA	216
4.6.1	Quantification of LA loading yield in composite membranes	216
4.6.2	The in vitro release profile of LA in simulated physiological solution	219
4.6.3	The in vitro release mechanism of LA in simulated physiological solution	221
4.7	In vitro antimicrobial efficacy assay on LA loaded composite membranes	224
4.7.1	Growth curves to determine mid-log exponential phase of bacteria	225
4.7.2	In vitro antimicrobial efficacy assay	226
4.8	Cytotoxicity assay on NAp and LA added PLGA composite membranes	233
4.9	Summary of overall findings	236

5	CONCLUSION AND FUTURE RECOMMENDATIONS	238
5.1	Conclusion	238
5.2	Limitations and Future recommendations	239
	REFERENCES	242
	Appendices A-I	265-310

LIST OF TABLES

TABLE NO.	TITLE	PAGE
2.1	List of commercially available non-resorbable GBR barrier membranes.	20
2.2	List of commercially available synthetic bioresorbable membranes.	23
2.3	Drawbacks of antibiotics in systemic administration and localised release systems.	35
3.1	Molar concentration of precursors used in the synthesis.	55
3.2	Freezing time for the formation of layered membranes. Composition of PLGA, NAp and LA varied in layer 1 (L1), layer 2 (L2) and layer 3 (L3) of the membranes.	72
3.3	Composition of NAp and LA added PLGA membranes used in reproducibility studies.	75
3.4	Varied composition of PLGA, NAp and LA in layer 1 (L1), layer 2 (L2) and layer 3 (L3) of the optimised membranes.	78
3.5	The composition of membrane samples tested for mechanical strength in dry and wet conditions.	86
3.6	Composition of membranes used for in vitro degradation test and lauric acid release studies.	88
3.7	Types of membranes used for extraction of LA and as control.	91
3.8	Membranes with various LA contents for loading efficiency studies.	92
3.9	The HPLC gradient elution profile using acetonitrile and water based mobile phase to quantify LA release in buffer medium.	95

- 4.1 Effect of various synthesis parameters on crystallite size, crystallinity, specific surface area and lattice parameters of as-prepared stoichiometric HA (NHA) and ions substituted apatite (NApF1 & NApF2) powders. 108
- 4.2 Molar concentrations of the precursors used in the synthesis of nanoapatite compared to actual molar concentrations obtained in the as-prepared powders by varying the (Ca & P) equimolar reactant concentrations and synthesis temperature. Reaction I involves synthesis at 37 ± 2 °C whereas in reaction II, NAp initially synthesised at 37 ± 2 °C which then increased to 85 ± 2 °C until completion of synthesis reaction. 118
- 4.3 Molar concentrations of the precursors used in the synthesis of nanoapatite compared to actual molar concentrations obtained in the as-prepared powders by reducing the substituents concentration (less than Table 4.2) and using 1.5M (Ca & P) reactant concentrations. 119
- 4.4 Repeated batches of NApF2 powders synthesized using 1.5 M (Ca & P) reactant concentrations indicating comparable reproducibility. 121
- 4.5 Average temperature changes during layering, TIPS and solvent leaching steps within 24 h of each membrane fabrication. 136
- 4.6 The photograph images of L1 and L2 surfaces of fabricated membranes containing various amounts of PLGA, NAp and LA. 139
- 4.7 The photograph images of fabricated membranes containing various amounts of NAp and LA in PLGA. PLGA was increased in L1 of membranes to produce less porous structure. 145
- 4.8 SEM micrographs and processing conditions of reproducible pure PLGA membranes. 153

4.9	SEM micrographs and processing conditions of reproducible 10 – 30 wt% of NAp + 1 wt% of LA added PLGA composite membranes.	154
4.10	SEM micrographs and processing conditions of reproducible 10 – 30 wt% of NAp + 2 wt% of LA added PLGA composite membranes.	155
4.11	SEM micrographs and processing conditions of reproducible 10 – 30 wt% of NAp + 3 wt% of LA added PLGA composite membranes.	156
4.12	Glass transition temperature of pure PLGA and composite membranes fabricated using various NAp and LA contents in PLGA matrices.	181
4.13	Mechanical properties of triple-layered membranes in dry and wet state. Data are presented as mean \pm SD, n=6.	186
4.14	Kinetic parameters of LA release from composite membrane using various mathematical modeling.	223

LIST OF FIGURES

FIGURE NO.	TITLE	PAGE
1.1	LA incorporation into barrier membrane as an antimicrobial agent for adjunct treatment in GBR procedures to inhibit bacterial infection.	7
1.2	Representation of thesis outline.	11
2.1	(a) An adequate bone volume (height and width) is a prerequisite for successful implant treatment. (b) Barrier membrane and bone graft as bone substitute materials are placed to accelerate bone formation. (c) Development of final prosthesis after the formation of new bone.	15
2.2	The principle of guided bone regeneration using barrier membranes to mechanically occlude soft tissue invasion and to retain blood clot in a secluded space. Bone growth occurs through bone cells migration from the surrounding original bone.	16
2.3	Structure of lactic acid, glycolic acid and poly (lactic-co-glycolic acid) (PLGA).	28
2.4	Structure of lauric acid.	37
2.5	Functionally graded and layered GBR barrier membrane.	40
3.1	The schematic illustration of LA and NAp incorporation into PLGA, forming composite membranes by combined techniques of solvent casting-TIPS-solvent leaching.	52
3.2	Process flow of experimental methods involved in the fabrication and evaluation of composite membranes.	53
3.3	Differences between synthesis reaction method I and II. In reaction method I (a), the synthesis process was carried	

- out and maintained at a lower temperature until the reaction is completed. In reaction method II (b), initially the complete ions addition was conducted at a lower temperature and subsequently maintained at an elevated temperature until the synthesis process is completed. 56
- 3.4 Process flow for the synthesis of multiple ions substituted non-stoichiometric nanoapatite (NAp). (a)-(c) The PO_4^{3-} , Na^+ and CO_3^{2-} ionic solutions were added slowly into the basic suspension containing Ca^{2+} , Mg^{2+} and K^+ precursors while vigorously stirring and heating it, (d) the precipitation product was filtered and washed using DDI water, (e) the dried cake was crushed, (f) crushed cake was ground to fine powders and (g) sieved through 500 μm and 20-50 μm mesh size. 58
- 3.5 The refrigerator thermometer placed in the freezing compartment to measure the temperature changes while placing composite solutions to induce phase separation. 73
- 3.6 Membrane fabrication steps via solvent casting and TIPS. (a-d) Weighed PLGA, LA and NAp separately for L1, L2 and L3, (e) mixed PLGA, LA and NAp in a vial, (f-g) sonicated composite solution, (h) solvent casting, and (i) cast solvent subjected to TIPS. 81
- 3.7 Washing steps for phase separated composite membranes. (a) Frozen and phase separated solution placed in cool water, (b-c) zoomed view of step (a) showing placement of petri dish (containing frozen composite solution) in a glass beaker filled with cool water, (d) membrane separated from petri dish and placed in a fresh cool water, (e) zoomed view of step (d) and finally room air dried composite membrane showing (f) L3 and (g) L1. 82
- 4.1 Triple layered composite PLGA membrane containing LA and NAp promoting bone cells growth while preventing bacteria and fibroblast cells. 106
- 4.2 XRD patterns of the as-prepared ions substituted apatite powder (NApF2-1.5M) synthesised at 37 ± 2 °C (reaction method I) and

	37 and 85 ± 2 °C (reaction method II).	107
4.3	XRD patterns of as-prepared ions substituted apatite (NApF2) synthesised at 37 and 85 ± 2 °C (reaction method II) using 1.0M, 1.5M and 2.0M equimolar precursors.	110
4.4	XRD patterns of as-prepared stoichiometric HA (NHA) and ions substituted apatite (NApF1 & NApF2) powders synthesised at 37 and 85 ± 2 °C (reaction method II) using 1.5M equimolar precursors.	111
4.5	TEM micrographs of as prepared HA synthesised at 37 ± 2 °C using reactant concentration (a) 1.0M, (b) 1.5M and (c-d) 2.0M at low magnification (a,b,c) and high magnification (d), respectively.	112
4.6	TEM micrographs of as-prepared NApF2 synthesised at 37 & 85 ± 2 °C using reactant concentration 1.5 M at low magnification on three different spots (a)-(c) and high magnification (d), respectively.	113
4.7	TGA and DTA curves of the stoichiometric HA (NHA) powders synthesised at 37 ± 2 °C using 1.0 M, 1.5 M and 2.0 M reactants and dried at 80 °C.	115
4.8	TGA and DTA curves of NHA, NApF1 and NApF2 powders initially synthesised at 37 ± 2 °C and then increased to 85 ± 2 °C (reaction II) using 1.5M reactants and dried at 80 °C. The samples denoted as 37 and 85 ± 2 °C.	117
4.9	FTIR spectra of as prepared stoichiometric HA (NHA) and ionic substituted apatite (NApF1 & NApF2) powders synthesised at 37 & 85 ± 2 °C (reaction method II) using 1.5 M equimolar precursors.	122
4.10	SEM micrograph for the morphology of (a) stoichiometric HA (NHA); ions substituted nanoapatite (b) NApF1 and (c) NApF2 powders synthesised at 37 and 85 ± 2 °C using 1.5 M reactant concentration (30,000× magnification).	124
4.11	XRD patterns of stoichiometric HA (NHA) and ionic substituted apatite (NApF1 & NApF2) powders synthesised at 37 & 85 ± 2 °C (reaction method II) using 1.5M equimolar	

- precursors after heat-treatment at 900 °C in CO₂ controlled atmosphere. 125
- 4.12 XRD patterns of stoichiometric HA (NHA) and ionic substituted apatite (NApF1 & NApF2) powders synthesised at 37 & 85±2 °C (reaction method II) using 1.5M equimolar precursors after sintering at 1250 °C in air. 126
- 4.13 FTIR spectra of stoichiometric HA (NHA) and ionic substituted apatite (NApF1 & NApF2) powders synthesised at 37 & 85± 2 °C (reaction method II) using 1.5 M equimolar precursors after heat-treatment at 900 °C in CO₂ controlled atmosphere. 128
- 4.14 FTIR spectra of stoichiometric HA (NHA) and ionic substituted apatite (NApF2) powders synthesised at 37 & 85±2 °C (reaction method II) using 1.5M equimolar precursors after sintering at 1250 °C in air. 130
- 4.15 Representative 24-well plates for qualitative AB colour changes. Colour change from blue to red indicates presence of live cells whereas unchanged blue colour indicates presence of dead cells after treatment with extracts. (a) NHA and (b) NApF2 powder extracts, and (c) positive control (phenol solution extracts). 131
- 4.16 Cytotoxicity assay results on L929 mouse fibroblast cells viability in response to different extract concentrations of NHA and NApF2 powder extracts. The data are presented as means ± SEM values of two independent experiments (*n* = 2). 132
- 4.17 SEM micrographs of L1 of composite membranes containing 10-30wt% NAp + 1wt% LA and 10-100wt% NAp + 1wt% LA graded in (a) 7, (b) 9, (c) 11 and (d) 13wt% of PLGA matrices. L1 of pure PLGA membranes were compared as control. (e) The representative EDS spectrum of the composite membranes taken on L1. 141

- 4.18 SEM micrographs of L3 of 10-30wt% NAp + 1wt% LA and 10-100wt% NAp + 1wt% LA graded membranes in (a) 7, (b) 9, (c) 11 and (d) 13wt% of PLGA matrices. L3 of pure PLGA membranes were compared as control. (e) The representative EDS spectrum of the composite membranes taken on L3. 142
- 4.19 SEM micrographs of L1 of (a) 15, (b) 17, (c) 20 and (d) 23wt% PLGA membranes. 144
- 4.20 Photographs of (a) L1 and (b) L3 of PLGA membranes with graded composition of 10-30 wt% NAp + 3 wt% LA and the representative SEM micrographs for (c) L1, (d) L3 and (e) cross section of membranes. 147
- 4.21 (A) Representative SEM micrographs of PLGA membranes (a)-(c) and 3 wt% of LA added composite PLGA membranes (d)-(f) on L1 surface. The representative micrographs of (a) & (d) as-prepared membranes, and membranes after immersion in ethanol for (b) & (e) 30 s and (c) & (f) 5min, respectively with magnification 100 x. Insets show high magnification (1000 x) view of the respective membranes. Crossed marks (x) indicate peeled-off spots. (B) FTIR spectra of 3 wt% of LA added (a) as-prepared membrane; and membranes after immersion in ethanol for (b) 30s and (c) 5 min; and (d) as-received LA and (e) pure PLGA membrane. 149
- 4.22 SEM micrographs of 3 wt% LA + 10-30 wt% NAp added PLGA composite membranes taken on (a) L1 and (b) L3 of as-prepared membranes, (c) 5 min immersed L3 surface of the membrane; and their respective EDS spectra. Crossed (x) marks indicate EDS points. 151
- 4.23 Representative EDS spectra of the L3 of composite membranes (Table 4.9 – 4.11 (c, f, i)) containing (a) 1 wt%, (b) 2 wt% and (c) 3 wt% LA and 10-30 wt% of NAp, confirming the presence of NAp particles within the membrane. 157

- 4.24 SEM micrographs of L1, L3 and cross-section of (a) pure PLGA membrane (S105) and (b) 1wt% (S98), (c) 2wt% (S99), (d) 3wt% (S100) of LA incorporated triple layered membranes containing 10-30 wt% of NAp in 9-20 wt% of PLGA matrices. (e) The representative EDS spectrum of the composite membrane. 159
- 4.25 SEM micrographs of L1, L3 and cross-section of (a) pure PLGA membrane (S105) and (b) 1wt% (S106), (c) 2 wt% (S107), (d) 3 wt% (S108) of LA incorporated triple layered membranes containing 10-100 wt% of NAp in 9-20 wt% of PLGA matrices. (e) The representative EDS spectrum of the composite membranes. 161
- 4.26 SEM micrographs of L1, L3 and cross-section of (a) pure PLGA membrane (S181) and (b) 1 wt% (S183), (c) 2 wt% (S185), (d) 3 wt% (S187) of LA incorporated triple layered membranes containing 10-30 wt% of NAp in 9-17 wt% of PLGA matrices. (e) The representative EDS spectrum of composite membranes. 163
- 4.27 SEM micrographs of L1, L3 and cross-section of (a) pure PLGA membrane (S181) and (b) 1 wt% (S193), (c) 2 wt% (S191), (d) 3 wt% (S189) of LA incorporated triple layered membranes containing 10-100 wt% of NAp in 9-17 wt% of PLGA matrices. (e) The representative EDS spectrum of composite membranes. 164
- 4.28 High magnification SEM micrographs of L1 (left) and L3 (right) of (a,b) 9-20 wt% of pure PLGA matrices (S105), (c,d) 3 wt% LA + 10-30 wt% NAp added in 9-20 wt% of PLGA matrices (S100), (e,f) 3 wt% LA + 10-100 wt% of NAp added in 9-20 wt% of PLGA matrices (S108). (g) The representative EDS spectrum of NAp particles on composite membranes as indicated by the black arrows in (c) and (e). 166

- 4.29 High magnification SEM micrographs of L1 (left) and L3 (right) of (a,b) 9-17wt% of pure PLGA matrices (S181), (c,d) 3 wt% LA + 10-30wt% NAp added in 9-17wt% of PLGA matrices (S187), (e,f) 3wt% LA + 10-100wt% of NAp added in 9-17wt% of PLGA matrices (S189). (g) The representative EDS spectrum of NAp particles as indicated by the white arrows in (d) and (f). 168
- 4.30 XRD patterns for (a) pure PLGA membrane (S105); L1 of 10-30wt% of NAp added in 9-20wt% of PLGA composite membrane containing (b) 1wt% (S98), (c) 2wt% (S99) and (d) 3wt% (S100) of LA. The opposite layers of L1, i.e., L3 were not introduced with LA. The XRD patterns of L3 were the opposite layers of L1 added with (e) 1wt% (S98), (f) 2wt% (S99) and (g) 3wt% (S100) of LA in triple layered membranes containing (h) NAp; (i) magnified region for NAp showing apatite (■) peaks, (j) LA. L1 and L3 were incorporated with 10 and 30wt% of NAp, respectively. 171
- 4.31 XRD patterns for (a) pure PLGA membrane (S105); L1 of 10-100wt% of NAp added in 9-20wt% of PLGA composite membrane containing (b) 1wt% (S106), (c) 2wt% (S107) and (d) 3wt% (S108) of LA. The opposite layers of L1, i.e., L3 were not introduced with LA. The XRD patterns of L3 were the opposite layers of L1 added with (e) 1wt% (S106), (f) 2wt% (S107) and (g) 3wt% (S108) of LA in triple layered membranes containing (h) NAp; (i) magnified region for NAp showing apatite (■) peaks, (j) LA. L1 and L3 were incorporated with 10 and 100wt% of NAp, respectively. 172
- 4.32 FTIR spectra of (a) as-received PLGA, (b) LA particles, (c) NAp powder and L1 surface of (d) pure PLGA (S112), (e) 1 wt% (S110), (f) 2 wt% (S102) and (g) 3 wt% (S115) of LA added composite membranes containing

	10-30 wt% of NAp in 9-20 wt% of PLGA matrices.	175
4.33	FTIR spectra of (a) NAp powder and L3 surface of (b) pure PLGA (S112) membrane (c) 1 wt% of LA (S117), (d) 2 wt% of LA (S118) and (e) 3 wt% of LA (S119) added composite membranes containing 10-100 wt% of NAp in 9-20 wt% of PLGA matrices.	177
4.34	The illustration of possible interaction mechanisms between PLGA-NAp-LA composite systems presenting (a) hydrogen bonding between PLGA-NAp-LA and (b) ionic bonding between NAp-LA.	179
4.35	DSC thermogram of LA.	180
4.36	DSC thermograms of pure PLGA membrane (S195), 1 wt% LA (S197), 2 wt% LA (S199) and 3 wt% LA (S201) added composite membranes containing 10-30 wt% of NAp in 9-20 wt% of PLGA matrices.	181
4.37	DSC thermograms of pure PLGA membrane (S195), 1 wt% LA (S203), 2 wt% LA (S205) and 3 wt% LA (S207) added composite membranes containing 10-100 wt% of NAp in 9-20 wt% of PLGA matrices.	182
4.38	Representative stress-strain curves of the 10-30 wt% of NAp added 9-20 wt% of PLGA composite membranes with different LA contents. Only one typical plot for each membrane is shown.	185
4.39	Tensile strength of 1-3 wt% of LA added composite membranes containing 10-30 wt% and 10-100 wt% NAp in 9-20 wt% of PLGA matrices. Data are presented as mean \pm SD, n=6.	187
4.40	Representative stress-strain curves of the 10-100 wt% of NAp containing 9-20 wt% of PLGA composite membranes with different LA contents. Only one typical plot for each membrane is shown.	189
4.41	Tensile strength of 1-3 wt% of LA added composite membranes containing 10-30 wt% and 10-100 wt% NAp	

- in 9-17 wt% of PLGA matrices. Data are presented as mean \pm SD, $n=6$. 192
- 4.42 The weight loss of 9-20 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 1 wt% of LA and NAp varied at 10-30 wt% and 10-100 wt%. Data are presented as mean \pm SD, $n =3$. 196
- 4.43 The weight loss of 9-20 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 2 wt% of LA and NAp varied at 10-30 wt% and 10-100 wt. Data are presented as mean \pm SD, $n =3$. 197
- 4.44 The weight loss of 9-20 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 3 wt% of LA with NAp varied at 10-30 wt% and 10-100 wt%. Data are presented as mean \pm SD, $n =3$. 198
- 4.45 SEM micrographs of L3 surfaces of pure PLGA and composite membranes (a) before immersion and after immersion for (b) 4 weeks, (c) 12 weeks and (d) 24 weeks in PBS. The PLGA content is 9-20 wt%. The PLGA content is 9-20 wt%. (e) The EDS spectrum of the region marked by rectangle taken on 10-100 wt% of NAp added composite membrane as in (d). 199
- 4.46 SEM micrographs of L3 surface morphology of pure PLGA (9-20 wt%) membrane, (a) before immersion and after immersion for (b) 4 weeks and (c) 24 weeks in PBS. 200
- 4.47 SEM micrographs of L1 surfaces of pure PLGA and composite membranes (a) before immersion and after immersion for (b) 4 weeks, (c) 12 weeks and (d) 24 weeks in PBS. The PLGA content is 9-20 wt%. (e) The EDS spectrum of the region marked by rectangle taken on 10-100 wt% of NAp added composite membrane as in (c). 201
- 4.48 The weight loss of 9-20 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 10-30 wt% of NAp and LA varied at 1-3 wt%.

	Data are presented as mean \pm SD, n=3.	202
4.49	The weight loss of 9-20 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 10-100 wt% of NAp and LA varied at 1-3 wt%.	
	Data are presented as mean \pm SD, n=3.	203
4.50	The weight loss of 9-17 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 3 wt% of LA and NAp varied at 10-30 wt% and 10-100 wt%. Data are presented as mean \pm SD, n=3.	204
4.51	SEM micrographs of L1 surface morphology of composite PLGA (9-17 wt%) membranes with 10-100 wt% of NAp and 3wt% LA, (a) before immersion and (b) after immersion for 24 weeks in PBS.	204
4.52	The pH change of 9-20 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 10-30 wt% of NAp and LA varied at 1-3 wt%.	
	Data are presented as mean \pm SD, n=3.	207
4.53	The pH change of 9-20 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 10-100 wt% of NAp and LA varied at 1-3 wt%.	
	Data are presented as mean \pm SD, n=3.	207
4.54	The pH change of 9-17 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 3 wt% of LA and NAp varied at 10-30 wt% and 10-100 wt%.	
	Data are presented as mean \pm SD, n=3.	209
4.55	The pH change of 9-20 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 3 wt% of LA and NAp varied at 10-30 wt% and 10-100 wt%.	
	Data are presented as mean \pm SD, n=3.	209
4.56	The water uptake of 9-20 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 10-30 wt% of NAp and LA varied at 1-3 wt%.	
	Data are presented as mean \pm SD, n=3.	210

4.57	The water uptake of 9-20wt% of pure PLGA and composite triple layered membranes. The composites loaded with 10-100wt% of NAp and LA varied at 1-3wt%. Data are presented as mean \pm SD, n=3.	211
4.58	The water uptake of 9-20 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 1 wt% of LA and NAp varied at 10-30 wt% and 10-100 wt%. Data are presented as mean \pm SD, n=3.	212
4.59	The water uptake of 9-20 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 2 wt% of LA and varied at 10-30 wt% and 10-100 wt% of NAp. Data are presented as mean \pm SD, n=3.	213
4.60	The water uptake of 9-20 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 3 wt% of LA and varied at 10-30 wt% and 10-100 wt% of NAp. Data are presented as mean \pm SD, n=3.	213
4.61	The water uptake of 9-17 wt% of pure PLGA and composite triple layered membranes. The composites loaded with 3 wt% of LA and varied at 10-30 wt% and 10-100 wt% of NAp. Data are presented as mean \pm SD, n=3.	214
4.62	The highest UV absorption intensity of derivatized LA at the concentration of 2000 μ g/mL and (b) the corresponding linear calibration standard curve. Data represents mean \pm SD of three replicates.	218
4.63	The cumulative release percentage of LA from 3 wt% of LA loaded composite membranes containing 10-30 wt% of NAp in 9-20 wt% of PLGA matrices. Data represents mean \pm SD of two replicates.	220
4.64	The cumulative amount of LA released from the formulated membrane fitted to Ritger-Peppas model.	221
4.65	The cumulative amount of LA released from the formulated membrane fitted to Higuchi model.	222
4.66	The cumulative amount of LA released from the formulated membrane fitted to First order kinetic	

- model. 222
- 4.67 The cumulative amount of LA released from the formulated membrane fitted to Zero order kinetic model. 223
- 4.68 Growth curve of *S. aureus* (ATCC 6538) grown at 37 °C in TSB. Data represents means ± SEM of three independent experiments ($n = 3$). 225
- 4.69 Growth curve of *P. aeruginosa* (ATCC 9027) grown at 37 °C in TSB. Data represents means ± SEM of three independent experiments ($n = 3$). 226
- 4.70 Antimicrobial activity of 1, 2, and 3 wt% of LA incorporated composite membranes compared to pure PLGA control group against *S. aureus*. The number of viable microbes on the membranes after 24 h was obtained using colony counting formation method. Data represents means ± SEM of two independent experiments ($n = 2$). 227
- 4.71 Antimicrobial activity. The recovery of *S. aureus* on LA incorporated membranes after 24 h of incubation at 37 °C. The number of viable microbes on (a) PLGA membrane, and (b) 1 wt%, (c) 2 wt% and (d) 3 wt% of LA incorporated membranes, was obtained using colony counting formation method. The representative TSA plates for all three replicates show *S.aureus* colony formation after incubation. The TSA plates (e) represent colony formation of recovered inoculums after serially diluted to 10^{-1} (left plate) and 10^{-2} (right plate). At higher dilution (10^{-2}), fewer colonies were formed on plates which indicate that serial dilutions of the recovered inoculums were performed appropriately. 229
- 4.72 Antimicrobial activity of 1, 2, and 3 wt% of LA incorporated composite membranes compared to pure PLGA control group against *P. aeruginosa*. The number of viable

- microbes on the membranes after 24 h was obtained using colony counting formation method. Data represents means \pm SEM of two independent experiments ($n = 2$). After 24 h of incubation, the bacteria colonies had increased by 10^2 in all samples compared to initial loading of *P. aeruginosa* which demonstrated growth of bacteria after incubation period. 230
- 4.73 The recovery of *P. aeruginosa* on LA incorporated membranes after 24 h of incubation at 37 °C. The number of viable microbes on (a) PLGA membrane, and (b) 1 wt%, (c) 2 wt% and (d) 3 wt% of LA incorporated membranes, was obtained using colony counting formation method. The representative TSA plates for all three replicates show formation of *P. aeruginosa* colonies after incubation. The TSA plates (e) represent colony formation of recovered inoculums after serially diluted to 10^{-3} (left plate) and 10^{-4} (right plate). At higher dilution (10^{-4}), fewer colonies were formed on plates which indicate that serial dilutions of the recovered inoculums were performed appropriately. The bacteria growth on LA added composite membranes was prominently higher than pure PLGA membranes as more dilutions were performed beyond 10^{-1} and 10^{-2} . 231
- 4.74 Representative 24-well plates for AB colour changes assessment. Cells exposed to extracts of (a) PLGA, (b) 1 wt% LA, (c) 2 wt% LA, (d) 3 wt% LA and (e) phenol solution. 234
- 4.75 Cytotoxicity assay results of the pure PLGA and LA added composite membranes. Data are means \pm SEM of two independent experiments ($n=2$). 235

LIST OF SYMBOLS

cfu	-	Colony forming unit
d	-	Interplanar spacing
Exo	-	Exothermic
k	-	drug release kinetic constant
m_0	-	Initial weight
m_1	-	Wet weight
m_2	-	Dry weight
M	-	Molar
M_t	-	Amount of drug released at time t
M_∞	-	Total amount of drug released
n	-	Diffusional exponent
R^2	-	Correlation coefficient
rad	-	Radian
t	-	time
T_g	-	Transition temperature
X_c	-	Crystallinity
X_s	-	Crystallite size
θ	-	Diffraction Angle
λ	-	Wavelength of X-ray beam

LIST OF ABBREVIATIONS

AMP	-	Antimicrobial peptide
ATCC	-	American Type Culture Collection
ASTM	-	American Society for Testing and Materials
ATR	-	Attenuated total reflectance
BET	-	Brunauer – Emmet – Teller
CaP	-	Calcium phosphate
CHN	-	Carbon, Hydrogen, Nitrogen elemental analysis
DSC	-	Differential scanning calorimetry
DDI	-	Double distilled de-ionised
DMSO	-	Dimethyl sulfoxide
DTA	-	Differential thermal analysis
d-PTFE	-	Dense polytetrafluoroethylene
ECACC	-	European Collection of Cell Cultures
e-PTFE	-	expanded PTFE
et al.	-	and others
FDA	-	US Food and Drug Administration
FESEM	-	Field Emission Scanning Electron Microscope
FGM	-	Functionally graded membrane
FTIR	-	Fourier Transform Infrared spectrophotometry
<i>F. nucleatum</i>	-	<i>Fusobacterium nucleatum</i>
FWHM	-	Full width at half maximum
GBR	-	Guided bone regeneration
HA	-	Hydroxyapatite
HPLC	-	High Performance Liquid Chromatography
HSF	-	Human Skin Fibroblast cells
ICP-AES	-	Inductively Coupled Plasma-Atomic Emission Spectroscopy
i.e.	-	that is

IC ₈₀	-	Inhibition concentration at 80% killing
ICDD	-	International Centre for Diffraction Data
ISO	-	International Organisation for Standardisation
LA	-	Lauric acid
L1	-	Layer 1
L2	-	Layer 2
L3	-	Layer 3
MEM	-	Minimum Essential Medium
MePEG	-	Methoxypoly(ethyleneglycol)
MIC	-	Minimum inhibition concentration
MTT	-	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NAp	-	Non-stoichiometric nanoapatite
NApF1	-	Non-stoichiometric nanoapatite Formulation 1
NApF2	-	Non-stoichiometric nanoapatite Formulation 2
NHA	-	Stoichiometric nanohydroxyapatite
OFP	-	Open Flap Debridement
OD	-	Optical density
PBS	-	Phosphate buffered saline
PCL	-	Polycaprolactone
PDL	-	Periodontal ligament
PDLLA	-	poly(DL-lactic) acid
<i>P. gingivalis</i>	-	<i>Porphyromonas gingivalis</i>
PGA	-	Polyglycolic acid
<i>P. intermedia</i>	-	<i>Prevotella intermedia</i>
PLA	-	Polylactic acid
PLLA	-	poly(L-lactic) acid
PLGC	-	poly (L-lactide-co-glycolide-ε-caprolactone)
PLCL	-	poly (L-lactide-co-ε-caprolactone)
PU	-	Polyetherurethane
PTFE	-	polytetrafluoroethylene
rpm	-	revolution per minute
SEM	-	Scanning Electron Microscopy
SD	-	Standard Deviation

TEM	-	Transmission Electron Microscopy
TGA	-	Thermogravimetric analysis
TIPS	-	Thermally induced phase separation
UV	-	Ultraviolet
UV-Vis	-	Ultraviolet-Visible
wt%	-	Weight percentage
XRD	-	X-ray Diffraction
β -TCP	-	β -tricalcium phosphate
3D	-	3 dimensional

LIST OF APPENDICES

APPENDICES	TITLE	PAGE
A	List of publications	265
A1	Published article 1	266
A2	Published article 2	268
A3	Published article 3	270
A4	Published article 4	272
B1	Calculation for the preparation of 1.0 M Ca(OH) ₂ and H ₃ PO ₄ reactants for the synthesis of NHA-1.0M.	274
B2	Calculation for the preparation of 1.5 M Ca(OH) ₂ and H ₃ PO ₄ reactants for the synthesis of NHA-1.5M.	275
B3	Calculation for the preparation of 2.0 M Ca(OH) ₂ and H ₃ PO ₄ reactants for the synthesis of NHA-2.0M.	276
B4	Calculation for the preparation of 1.0 M Ca(OH) ₂ , H ₃ PO ₄ reactants and ionic solutions for the synthesis of NApF1 and NApF2-1.0M.	277
B5	Calculation for the preparation of 1.5 M Ca(OH) ₂ , H ₃ PO ₄ reactants and ionic solutions for the synthesis of NApF1 and NApF2-1.5M.	278
B6	Calculation for the preparation of 2.0 M Ca(OH) ₂ , H ₃ PO ₄ reactants and ionic solutions for the synthesis of NApF1 and NApF2-2.0M.	279
C1	Lattice parameters calculation for as prepared stoichiometric nanohydroxyapatite (NHA) powder synthesized using reaction method I (37±2°C).	280
C2	Lattice parameters calculation for as prepared stoichiometric nanohydroxyapatite (NHA) powder	

	synthesized using reaction method II ($37\pm 85\pm 2^\circ\text{C}$).	281
C3	Lattice parameters calculation for as prepared non-stoichiometric nanoapatite (NApF1) powder synthesized using reaction method I ($37\pm 2^\circ\text{C}$).	282
C4	Lattice parameters calculation for as prepared non-stoichiometric nanoapatite (NApF1) powder synthesized using reaction method II ($37\pm 85\pm 2^\circ\text{C}$).	283
C5	Lattice parameters calculation for as prepared non-stoichiometric nanoapatite (NApF2) powder synthesized using reaction method I ($37\pm 2^\circ\text{C}$).	284
C6	Lattice parameters calculation for as prepared non-stoichiometric nanoapatite (NApF2) powder synthesized using reaction method II ($37\pm 85\pm 2^\circ\text{C}$).	285
C7	Lattice parameters calculation for NHA, NApF1 and NApF2 powders sintered at 900°C in CO_2 .	286
C8	Lattice parameters calculation for NHA powders sintered at 900°C in CO_2 .	287
C9	Lattice parameters calculation for NApF1 powders sintered at 900°C in CO_2 .	288
C10	Lattice parameters calculation for NApF2 powders sintered at 900°C in CO_2 .	289
C11	Lattice parameters calculation for NHA, NApF1 and NApF2 powders sintered at 1250°C in air.	290
C12	Crystallite size (X_s in nm) of as prepared nanohydroxyapatite powders determined using Scherrer equation.	291
C13	Fraction of crystalline phase (X_c) of the as prepared NHA, NApF1 and NApF2 powders.	292
D1	Dry and wet tensile strength of 10-30 wt% of NAp containing 1-3 wt% of LA added PLGA (9-20wt%) composite membranes.	293
D2	Dry and wet tensile strength of 10-100 wt% of NAp containing 1-3 wt% of LA added PLGA (9-20wt%) composite membranes.	294

D3	Dry and wet tensile strength of 10-30 wt% of NAp containing 1-3 wt% of LA added PLGA (9-17wt%) composite membranes.	295
D4	Dry and wet tensile strength of 10-100 wt% of NAp containing 1-3 wt% of LA added PLGA (9-17wt%) composite membranes.	296
E1	Weight loss measurements and weight loss difference in post-immersed membranes added with 1-2wt% of LA and varied with 10-30 wt% and 10-100wt% NAp.	297
E2	Weight loss measurements and weight loss difference in post-immersed membranes added with 3 wt% of LA and varied with 10-30 wt% and 10-100wt% NAp.	298
E3	Weight loss measurements of 9-20 wt% PLGA membranes loaded with 10-30wt% and 10-100wt% of NAp and LA varied at 1-3 wt%.	299
E4	pH measurements of 9-20 wt% membranes containing 10-30 wt% and 10-100 wt% NAp and LA varied at 1-3wt%.	300
E5	pH measurements of 9-17 wt% and 9-20 wt% membranes containing 10-30 wt% and 10-100 wt% NAp and LA loaded at 3wt%.	301
F1	Comparison of water uptake in membranes containing 10-30wt% and 10-100wt% of NAp and LA varied at 1-3wt%.	302
F2	Comparison of water uptake in membranes containing LA loaded at 1 & 2wt% and NAp varied at 10-30wt% and 10-100wt%.	303
F3	Comparison of water uptake in membranes containing LA loaded at 3wt% and NAp varied at 10-30wt% and 10-100wt% in 9-20 wt% and 9-17wt% of PLGA matrices.	304
G1	Data for standard calibration curve and loading efficiency studies.	305
G2	Calculations for LA release from 3wt% of LA loaded composite membrane containing 10-30wt% of NAp in 9-20wt% of PLGA matrices (Sample A).	306

G3	Calculations for LA release from 3wt% of LA loaded composite membrane containing 10-30wt% of NAp in 9-20wt% of PLGA matrices (Sample B).	307
G4	Calculations for average LA release from 3wt% of LA loaded composite membrane containing 10-30wt% of NAp in 9-20wt% of PLGA matrices (Sample A+B).	308
H	Data for <i>S. aureus</i> and <i>P. aeruginosa</i> growth inhibition against LA concentration.	309
I	Data for cell viability of membrane samples.	310

CHAPTER 1

INTRODUCTION

1.1 Background

Rapid bone defect filling with normal bone is a challenge in the fields of orthopaedic and dentistry [1]. The bone has limited regeneration capability due to insufficient blood supply, large defects and invasion of highly proliferative nonosteogenic tissues that can impair bone repair [2,3]. Bone grafting is an established treatment to restore bone tissue. However, problems such as redundant fibrous connective tissue growth surrounding implanted bone graft and the movement of bone graft particles are still remain to be solved [1]. GBR has become an area of increasing interest in bone restorative procedures for guiding bone healing and regeneration [2,3] due to its success in curing cranial, maxillofacial and alveolar bone defects [4,5]. The concept of GBR is to cover the bone defect using a barrier membrane that enhances new bone ingrowth while preventing the ingrowth of fibrous tissue into the grafted site [6]. Hence, the bone regenerative approaches using GBR membranes have been extensively investigated to reveal their clinical potential [7,8,9].

GBR membranes have been widely studied as they are useful for bone repair in oral and maxillofacial surgery where limited mechanical loading exists [5,10]. The commercially available GBR membranes are made of non-resorbable and resorbable polymers. The non-resorbable polytetrafluoroethylene (PTFE) membranes have exhibited significant disadvantages such as requirement for second surgery and increased risk of infection leading to early removal of the membrane [9].

Collagen based resorbable membranes are widely used in clinical therapies. Since majority collagen membranes are animal derived, these membranes carry the risk of potential transmission of infectious agents, including the inappropriate immune responses in patients [7]. The synthetic resorbable membranes have found widespread use in clinical medicine as they are totally degradable, thus not requiring second surgery [8,9]. Poly(lactic-co-glycolic acid) (PLGA) is a FDA approved synthetic resorbable material and widely used in GBR applications [11,12]. Nonetheless, an inflammatory reaction by the accumulation of acidic degradation products in resorbable membranes has been reported [4,13]. The combination of calcium phosphate (CaP) with resorbable polymeric membranes is expected to neutralize the acidic degradation products from the membranes; which is intended to overcome inflammatory reaction in vivo [13,14,12,15,16]. Moreover, CaP particles in polymeric membranes has been also reported to improve structural integrity, flexibility and bone regeneration in vivo [17,15,18,14]. The aforementioned studies emphasises the need for incorporation of CaP particles to improve physical and mechanical properties of the resorbable polymeric membrane.

Currently, biomaterial-associated infection is regarded as a devastating complication in clinical surgery. Therefore, anti-infective biomaterials need to be developed as the main strategy to prevent infection in clinical applications [19]. A bacteria-free environment is highly important to regenerate bone tissues in GBR strategies [20]. Recently, the antibiotics incorporated GBR membranes have been developed for local delivery of antimicrobial agents [21]. Nonetheless, the increasing bacterial resistance prompted the development of alternative antimicrobial agent incorporated GBR membranes [22,23,20,24]. In light of this, a naturally derived antimicrobial agent to substitute the use of antibiotics is sought after to develop a new antimicrobial membrane for clinical applications.

The antimicrobial properties of naturally found fatty acids have been recognized for many years. Lauric acid (LA) is naturally found in coconut oil [25] and has been recognized to possess broad-spectrum with effective antimicrobial activity against gram-positive bacteria [26,27]. Unlike antibiotics, fatty acids and their derivatives have diverse modes of action that appear to be non-specific and

development of resistance to these compounds has not been reported [28]. It is suggested that LA kills Gram-positive bacteria by separating their inner and outer membranes, resulting in cytoplasmic disorganization of the bacteria [25]. Thus, it is envisaged that incorporating LA in composite membranes for anti-infective bone regeneration purposes could possibly overcome clinical complications caused by the administration of antibiotics.

The development of functionally graded and multiple layered membrane is to enhance the features required for GBR, namely a combination of physical, mechanical, biological and antimicrobial properties [13,23]. Also, the incorporation of functional gradients in a multilayered membrane structure offers the possibilities to overall usefulness to the membrane. Solvent casting technique offers the formation of layered membrane structure [16] whereas porous network formation is attainable through thermally induced phase separation (TIPS) [29] of the polymeric materials. The presence of residual toxic organic solvent is a major concern in solvent based fabrication technique. Thus, it is vital to include solvent removal step to reduce possible toxicity by solvent residues in fabricated membranes [30]. In this study, a new modified solvent casting-TIPS-solvent leaching technique is proposed to fabricate triple layered and graded composite PLGA membrane. Collectively, it is suggested that a new combination of CaP nanoparticles and LA as an antimicrobial agent being graded and layered in PLGA matrices can potentially function as an antimicrobial barrier membrane. This thesis will advance the knowledge in the area of antimicrobial composite membrane development for potential use in cranial, maxillofacial and dental applications. A new technique to establish the fabrication of multilayered and graded composite membrane utilizing solvent casting-TIPS-solvent leaching technique will be developed in this study. The fabrication and structural properties of the triple-layered PLGA membrane, graded with various amounts of LA and CaP nanoapatite will be studied. The effects of LA and CaP addition on the physical, chemical, mechanical, biological and antimicrobial properties of the PLGA composite membrane will also be explored. This membrane will deliver antimicrobial and osteoconductive properties by the incorporation of LA and CaP nanoapatite, respectively.

1.2 Problem statements

The major concerns in GBR surgical intervention are the problems related to the increasing bacterial resistance and side effects caused by antibiotics [31,32]. Multiple antibiotics are currently used to protect the bone defect from bacterial invasion, increasing the risks of bacterial resistance and side effects [33,22,31]. Hence, an alternative antimicrobial agent to substitute antibiotics is sought after. LA has been exhibiting effective antimicrobial activity against gram-positive bacteria that eliminates the need for multiple antibiotics to prevent bacteria colonization [26,27]. Therefore, the incorporation of antimicrobial LA in the composite membrane and its controlled release is proposed to circumvent the above mentioned drawbacks.

Apart from antimicrobial property, other important membrane characteristics such as surface morphology, pore size, membrane degradability, mechanical properties and cytocompatibility should be equally evaluated. Hence, appropriate materials selection and membrane design for GBR applications are highly indispensable for a successful bone defect treatment [7]. Poly(lactic-co-glycolic acid) (PLGA) is a FDA approved synthetic resorbable material which is widely used in GBR applications [11,12]. However, the accumulations of acidic degradation products from the synthetic bioresorbable membranes have been reported to cause inflammatory reaction in vivo [8,9]. Hence, the combination of synthetic polymers with CaP has been reported to neutralize the acidic degradation products from the polymers using ionic interactions [13,14,12,15,16]. Moreover, CaP incorporation improves structural integrity, flexibility and bone regeneration of the resorbable membranes [17,15,18,14]. Therefore, the current clinical disadvantage of using pure synthetic polymeric material as a GBR membrane could be overcome by incorporating CaP particles to reduce the potential inflammatory reactions. Thus, in this study, multiple ions substituted nanoapatite (NAP) powder which has close resemblance to natural bone mineral composition will be synthesized and incorporated into the PLGA matrices to form composite membranes.

Incorporating multiple additives in a composite membrane is a challenge as it requires the development of multilayered and graded membrane structure [13,16,34]. In order to address GBR applications, two functional surface layers are required. One of the surfaces with porous morphology allows bone ingrowth whereas the other dense surface prevents fibrous tissue penetration [16,13]. Therefore, in this study a triple-layered composite membrane with new combination of porous/dense layers will be developed. The NAp particles and LA will be graded in each layer to deliver osteoconductive and antimicrobial properties, respectively.

In order to develop a multilayered and graded composite membrane, an appropriate technique is indispensable to achieve the desired membrane structure. Currently, solvent casting [16] and TIPS [29] techniques have been employed to fabricate composite membranes. However, there are two disadvantages of using solvent casting method: i) toxic organic solvents application [15,18] that requires critical attention especially on its exposure in biomedical applications, ii) CaP particles can spontaneously precipitate from the polymer solution due to poor affinity and can cause non-uniform dispersion of CaP in polymer matrix [18]. Hence, these drawbacks could be overcome by freezing the CaP dispersed polymer matrix structure through TIPS technique. Moreover, solvent removal from the fabricated membrane is another important step to reduce toxic solvent residues [30,35]. Hence, in this study, composite membranes will be fabricated utilizing a new combination of solvent casting-TIPS-solvent leaching technique to address the formation of layered and graded membrane, dispersed with CaP particles and removal of toxic solvent from the membrane. The new modified technique is envisaged to form a composite membrane with graded porous/dense structure that has functional gradients, i.e., NAp and LA.

1.3 Objectives of the study

This work explores a novel fabrication technique, structure and design of a polymer-ceramic composite membrane incorporating LA as an antimicrobial agent. The goal is to design a functionally graded triple layered barrier membrane with

antimicrobial property using solvent casting-TIPS-solvent leaching techniques. In order to achieve the main objective, the following specific objectives were executed.

- a) To synthesise multiple ions substituted non-stoichiometric nanoapatite (NAP) powder.
- b) To establish a combined solvent casting-TIPS-solvent leaching techniques for the formation of triple-layered PLGA composite membranes graded with LA and NAP powder.
- c) To determine the physical, chemical, mechanical and in vitro degradation properties of the membrane.
- d) To evaluate the cytocompatibility and antimicrobial efficacy of the membrane.

1.4 Research hypothesis

It is possible to achieve an antimicrobial composite membrane by incorporating antimicrobial agents, in order to prevent biomaterial-associated infection in GBR applications. Therefore, it is envisaged that incorporating LA in the composite membrane could impart antimicrobial property which could prevent bacterial infection associated to the membrane. Furthermore, a resorbable composite membrane is desired to achieve less in vivo inflammation by reducing acidic degradation products through the addition of CaP particles [8,9]. Moreover, the combination of synthetic resorbable membranes with CaP is expected to deliver improved mechanical strength to the composite membranes [17,15,18,14]. Hence, in this study, it is hypothesised that varying the NAP and LA contents in PLGA matrices can significantly alter the physico-chemical, mechanical and antimicrobial properties of the membrane.

The GBR membrane is designed to have a smooth surface on one face to inhibit soft tissue penetration while the opposite porous face is capable of accommodating bone tissue ingrowth in vivo [16,36]. The dense/porous network formation through TIPS [29] technique is easily attainable whereas a multilayered membrane structure via solvent casting and the removal of solvent [30] could translate a safer membrane fabrication technique for clinical practice. The solvent

casting-TIPS-solvent leaching technique will be used to test the hypothesis that one can tailor the properties of the different layers to form a functionally graded composite membrane to retain its structural, dimensional and mechanical properties for bone regeneration. Figure 1.1 demonstrates the importance of incorporating LA in composite membrane which may prevent bacterial infection on the membrane surface. In addition, formation of dense membrane surface also excludes fibroblast penetration into the barrier membrane.




Figure 1.1: LA incorporation into barrier membrane as an antimicrobial agent for adjunct treatment in GBR procedures to inhibit bacterial infection.

1.5 Scope of the study

A new design of triple-layered and graded PLGA composite membrane has been fabricated. The triple layered membrane is comprised of PLGA matrix, graded with non-stoichiometric NAp and LA at each layer. PLGA with a lactic acid to glycolic acid ratio of 85:15 degrade over 2–6 months [37] and have the ability to deliver drugs locally in a controlled manner. These properties are making it suitable for use as a GBR barrier membrane. Besides improving mechanical strength of the membranes, the incorporation of CaP particles should be merely targeted for its

osteoconductivity and hydrophilic nature to enhance bone growth into the polymer surfaces [38]. NAp powder is synthesized by introducing substituents within 1.84wt% (Na), 1.46wt% (Mg), 0.06wt% (K) and 4.80wt% (CO_3^{2-}) to closely mimic natural bone apatite. The NAp powder is incorporated to enhance bioactivity and osteoconductivity of the membrane. LA is added to introduce antimicrobial properties to the composite membrane to prevent bacterial infection as it is known to possess effective antimicrobial activity against gram-positive bacteria [26,27]. The composite membrane is fabricated by employing a modified solvent casting-TIPS-solvent leaching technique. The solvent casting facilitated lamination of multiple layers of graded LA and NAp in PLGA matrices whereas TIPS used to form porous/dense layers in the membrane structure. Solvent leaching is performed to remove toxic solvent residues.

1.6 Significance of the study

LA, as a substitute for antibiotics is identified and incorporated in the composite membrane which is to be used as a potential antimicrobial membrane for clinical applications. Prevention of bacterial infection is a promising strategy whereby LA imparts antimicrobial activity on the membrane surface. This would render an antimicrobial barrier membrane appropriate for adjunctive treatment in guiding bone regeneration. This work also reports the fabrication of PLGA-NAp-LA composite membrane using solvent casting-TIPS-solvent leaching technique. This new technique largely eliminates the solvent residue in the fabricated membrane through solvent leaching step using water as the exchanging medium.

1.7 Thesis outline

Chapter 1 is the introduction to the study of this thesis. The entire outline of the thesis is illustrated in Fig. 1.2.

Chapter 2 describes the review of literatures related to the development and application of commercially available GBR membrane that has been related to its profound improvement through current research to overcome clinically reported shortcomings. Moreover, selection criteria for PLGA, LA and NAp are also reviewed to ensure the fabricated composite membrane is more likely to possess appropriate physical, structural, dimensional, mechanical, antimicrobial and biological properties for potential use in bone regeneration procedures.

Chapter 3 deals with the materials and methods used to investigate the appropriate parameters, experimental set-up, test conditions, characterization using analytical equipment and material evaluation involved in the fabrication and evaluation of the composite membranes. The synthesis of NAp powder is reported in the first part of the chapter. Subsequently, the development of PLGA based NAp-LA composite membrane through a new fabrication technique using solvent casting-TIPS-solvent leaching is reported. This is followed by the development of methods to test on the membrane's properties such as physico-chemical, mechanical, in vitro degradation profile over six months duration, quantification of LA release and finally, LA release mechanism; since the effects of NAp and LA additions in the PLGA membranes are highly imperative to meet the design criteria of membranes for GBR applications.

Chapter 4 elaborates the outcome of NAp synthesis, fabrication of composite membranes, degradation profiles for composite membranes, mechanical evaluation of membranes in dry and wet condition, released LA concentration and its release mechanism. Synthesis of NAp with the highest substituent composition, the morphology of triple layered membrane, phase composition, physical changes in amorphous/crystalline state of LA, interaction mechanisms between PLGA-NAp-LA in composite membranes, weight loss and water absorption of membranes, and finally the quantification of LA release and its release mechanism from composite membranes for sufficient antimicrobial effects while maintaining its cytocompatibility are discussed. The cytocompatibility of synthesized NAp powder and composite membranes along with antimicrobial evaluation on the effects of LA addition in composite membranes were discussed.

Chapter 5 concludes structural, dimensional and mechanical integrity of the layered and graded composite membrane. The effects of LA and NAp addition on physico-chemical, mechanical and antimicrobial properties are also described.

Publications and presentations at conferences: This section forms part of the thesis, which described the synthesis of NAp powder and the fabrication of composite membranes published in peer reviewed impact factor journals and presented at international conferences as listed in Appendix A.




Figure 1.2: Representation of thesis outline.

REFERENCES

1. Cai, Y., Guo, J., Chen, C., Yao, C., Chung, S.-m., Yao, J., Lee, I.-s. and Kong, X. Silk fibroin membrane used for guided bone tissue regeneration. *Materials Science & Engineering C*. 2017. 70: 148-154.
2. Pasetto, S., Herculano, R.D., Ereno, C., Silva, P., Graeff, C.F.O., Tavano, O., Baffa, O. and Kinoshita, A. Latex use as an occlusive membrane for guided bone regeneration. *Journal of Biomedical Materials Research A*. 2010. 932-939.
3. Moura, J.M.L., Ferreira, J.F., Marques, L., Holgado, L., Graeff, C.F.O. and Kinoshita, A. Comparison of the performance of natural latex membranes prepared with different procedures and PTFE membrane in guided bone regeneration (GBR) in rabbits. *Journal of Materials Science: Materials in Medicine*. 2014. 25(9): 2111-2120.
4. Fujihara, K., Kotaki, M. and Ramakrishna, S. Guided bone regeneration membrane made of polycaprolactone/calcium carbonate composite nanofibers. *Biomaterials*. 2005. 26(19): 4139-4147.
5. Kellomäki, M., Niiranen, H., Puumanen, K., Ashammakhi, N., Waris, T. and Törmälä, P. Bioabsorbable scaffolds for guided bone regeneration and generation. *Biomaterials*. 2000. 21(24): 2495-2505.
6. Yang, F., Both, S.K., Yang, X., Walboomers, X.F. and Jansen, J.A. Development of an electrospun nano-apatite/PCL composite membrane for GTR/GBR application. *Acta Biomaterialia*. 2009. 5(9): 3295-3304.
7. Jung, R.E., Kokovic, V., Jurisic, M., Yaman, D., Subramani, K. and Weber, F.E. Guided bone regeneration with a synthetic biodegradable membrane: a comparative study in dogs. *Clinical Oral Implants Research*. 2011. 22(8): 802-807.
8. von Arx, T., Cochran, D.L., Schenk, R.K. and Buser, D. Evaluation of a prototype trilayer membrane (PTLM) for lateral ridge augmentation: an

- experimental study in the canine mandible. *International Journal of Oral and Maxillofacial Surgery*. 2002. 31(2): 190-199.
9. van Leeuwen, A.C., Huddleston Slater, J.J.R., Gielkens, P.F.M., de Jong, J.R., Grijpma, D.W. and Bos, R.R.M. Guided bone regeneration in rat mandibular defects using resorbable poly(trimethylene carbonate) barrier membranes. *Acta Biomaterialia*. 2012. 8(4): 1422-1429.
 10. Peltola, O.L.J., Asikainen, A.J., Nojonen, J. and Mesim, K.A. Tyrosine derived polycarbonate membrane is useful for guided bone regeneration in rabbit mandibular defects. *Journal of Materials Science: Materials in Medicine*. 2005. 16: 753-758.
 11. Jazayeri, H.E., Tahriri, M., Razavi, M., Khoshroo, K., Fahimipour, F., Dashtimoghadam, E., Almeida, L. and Tayebi, L. A current overview of materials and strategies for potential use in maxillofacial tissue regeneration. *Materials Science & Engineering C*. 2017. 70: 913-929.
 12. Liao, S., Watari, F., Zhu, Y., Uo, M., Akasaka, T., Wang, W., Xu, G. and Cui, F. The degradation of the three layered nano-carbonated hydroxyapatite/collagen/PLGA composite membrane in vitro. *Dental Materials*. 2007. 23(9): 1120-1128.
 13. Bottino, M.C., Thomas, V. and Janowski, G.M. A novel spatially designed and functionally graded electrospun membrane for periodontal regeneration. *Acta Biomaterialia*. 2011. 7(1): 216-224.
 14. Kikuchi, M., Koyama, Y., Yamada, T., Imamura, Y., Okada, T., Shirahama, N., Akita, K., Takakuda, K. and Tanaka, J. Development of guided bone regeneration membrane composed of β -tricalcium phosphate and poly (l-lactide-co-glycolide-co- ϵ -caprolactone) composites. *Biomaterials*. 2004. 25(28): 5979-5986.
 15. Puppi, D., Chiellini, F., Piras, A.M. and Chiellini, E. Polymeric materials for bone and cartilage repair. *Progress in Polymer Science*. 2010. 35(4): 403-440.
 16. Liao, S., Wang, W., Uo, M., Ohkawa, S., Akasaka, T., Tamura, K., Cui, F. and Watari, F. A three-layered nano-carbonated hydroxyapatite /collagen /PLGA composite membrane for guided tissue regeneration. *Biomaterials*. 2005. 26(36): 7564-7571.

17. Song, X., Ling, F., Ma, L., Yang, C. and Chen, X. Electrospun hydroxyapatite grafted poly(l-lactide)/poly(lactic-co-glycolic acid) nanofibers for guided bone regeneration membrane. *Composites Science and Technology*. 2013. 79: 8-14.
18. Zhou, H., Lawrence, J.G. and Bhaduri, S.B. Fabrication aspects of PLA-CaP/PLGA-CaP composites for orthopedic applications: A review. *Acta Biomaterialia*. 2012. 8(6): 1999-2016.
19. Campoccia, D., Montanaro, L. and Arciola, C.R. A review of the clinical implications of anti-infective biomaterials and infection-resistant surfaces. *Biomaterials*. 2013. 34(33): 8018-8029.
20. Münchow, E.A., Albuquerque, M.T.P., Zero, B., Kamocki, K., Piva, E., Gregory, R.L. and Bottino, M.C. Development and characterization of novel ZnO-loaded electrospun membranes for periodontal regeneration. *Dental Materials*. 2015. 31(9): 1038-1051.
21. Chen, D.W.C., Lee, F.Y., Liao, J.Y., Liu, S.J., Hsiao, C.Y. and Chen, J.K. Preclinical Experiments on the Release Behavior of Biodegradable Nanofibrous Multipharmaceutical Membranes in a Model of Four-Wall Intrabony Defect. *Antimicrobial Agents and Chemotherapy*. 2012. 57(1): 9-14.
22. Ji, W., Wang, H., van den Beucken, J.J.J.P., Yang, F., Walboomers, X.F., Leeuwenburgh, S. and Jansen, J.A. Local delivery of small and large biomolecules in craniomaxillofacial bone. *Advanced Drug Delivery Reviews*. 2012. 64(12): 1152-1164.
23. Bottino, M.C., Thomas, V., Schmidt, G., Vohra, Y.K., Chu, T.-M.G., Kowolik, M.J. and Janowski, G.M. Recent advances in the development of GTR/GBR membranes for periodontal regeneration—A materials perspective. *Dental Materials*. 2012. 28(7): 703-721.
24. de Breij, A., Riool, M., Kwakman, P.H.S., de Boer, L., Cordfunke, R.A., Drijfhout, J.W., Cohen, O., Emanuel, N., Zaat, S.A.J., Nibbering, P.H. and Moriarty, T.F. Prevention of Staphylococcus aureus biomaterial-associated infections using a polymer-lipid coating containing the antimicrobial peptide OP-145. *Journal of Controlled Release*. 2016. 222: 1-8.
25. Yang, D., Pornpattananankul, D., Nakatsuji, T., Chan, M., Carson, D., Huang, C.-M. and Zhang, L. The antimicrobial activity of liposomal lauric

- acids against *Propionibacterium acnes*. *Biomaterials*. 2009. 30(30): 6035-6040.
26. Bergsson, G., Arnfinnsson, J., Steingrímsson, O. and Thormar, H. In Vitro Killing of *Candida albicans* by Fatty Acids and Monoglycerides. *Antimicrobial Agents and Chemotherapy*. 2001. 45(11): 3209-3212.
 27. Rouse, M.S., Rotger, M., Piper, K.E., Steckelberg, J.M., Scholz, M., Andrews, J. and Patel, R. In Vitro and In Vivo Evaluations of the Activities of Lauric Acid Monoester Formulations against *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy*. 2005. 49(8): 3187-3191.
 28. Nobmann, P., Bourke, P., Dunne, J. and Henehan, G. In vitro antimicrobial activity and mechanism of action of novel carbohydrate fatty acid derivatives against *Staphylococcus aureus* and MRSA. *Journal of Applied Microbiology*. 2010. 108: 2152-61.
 29. Ho, M.-H., Hsieh, C.-C., Hsiao, S.-W. and Van Hong Thien, D. Fabrication of asymmetric chitosan GTR membranes for the treatment of periodontal disease. *Carbohydrate Polymers*. 2010. 79(4): 955-963.
 30. Rowlands, A.S., Lim, S.A., Martin, D. and Cooper-White, J.J. Polyurethane/poly(lactic-co-glycolic) acid composite scaffolds fabricated by thermally induced phase separation. *Biomaterials*. 2007. 28(12): 2109-2121.
 31. Schwach-abdellaoui, K., Vivien-castioni, N. and Gurny, R. Local delivery of antimicrobial agents for the treatment of periodontal diseases. *European Journal of Pharmaceutics and Biopharmaceutics*. 2000. 50: 83-99.
 32. Sweeney, L.C. Antibiotic resistance in general dental practice--a cause for concern? *Journal of Antimicrobial Chemotherapy*. 2004. 53(4): 567-576.
 33. Herrera, D., Matesanz, P., Bascones-Martínez, A. and Sanz, M. Local and Systemic Antimicrobial Therapy in Periodontics. *Journal of Evidence Based Dental Practice*. 2012. 12(3): 50-60.
 34. Sun, F., Zhou, H. and Lee, J. Various preparation methods of highly porous hydroxyapatite/polymer nanoscale biocomposites for bone regeneration. *Acta Biomaterialia*. 2011. 7(11): 3813-3828.
 35. Vaquette, C. and Cooper-White, J. A simple method for fabricating 3-D multilayered composite scaffolds. *Acta Biomaterialia*. 2013. 9(1): 4599-4608.

36. Carlo Reis, E.C., Borges, A.P.B., Araújo, M.V.F., Mendes, V.C., Guan, L. and Davies, J.E. Periodontal regeneration using a bilayered PLGA/calcium phosphate construct. *Biomaterials*. 2011. 32(35): 9244-9253.
37. Owen, G.R., Jackson, J.K., Chehroudi, B., Brunette, D.M. and Burt, H.M. An in vitro study of plasticized poly(lactic-co-glycolic acid) films as possible guided tissue regeneration membranes: Material properties and drug release kinetics. *Journal of Biomedical Materials Research Part A*. 2010. 95A(3): 857-869.
38. Lee, E.-J., Teng, S.-H., Jang, T.-S., Wang, P., Yook, S.-W., Kim, H.-E. and Koh, Y.-H. Nanostructured poly(ϵ -caprolactone)-silica xerogel fibrous membrane for guided bone regeneration. *Acta Biomaterialia*. 2010. 6(9): 3557-3565.
39. Yu, Z., Geng, J., Gao, H., Zhao, X. and Chen, J. Evaluations of guided bone regeneration in canine radius segmental defects using autologous periosteum combined with fascia lata under stable external fixation. *Journal of Orthopaedics and Traumatology*. 2015. 16(2): 133-140.
40. Fu, S., Ni, P., Wang, B., Chu, B., Zheng, L., Luo, F., Luo, J. and Qian, Z. Injectable and thermo-sensitive PEG-PCL-PEG copolymer/collagen/n-HA hydrogel composite for guided bone regeneration. *Biomaterials*. 2012. 33(19): 4801-4809.
41. Lee, Y.J., Lee, J.-H., Cho, H.-J., Kim, H.K., Yoon, T.R. and Shin, H. Electrospun fibers immobilized with bone forming peptide-1 derived from BMP7 for guided bone regeneration. *Biomaterials*. 2013. 34(21): 5059-5069.
42. Lee, E.-J., Shin, D.-S., Kim, H.-E., Kim, H.-W., Koh, Y.-H. and Jang, J.-H. Membrane of hybrid chitosan-silica xerogel for guided bone regeneration. *Biomaterials*. 2009. 30(5): 743-750.
43. Jung, R.E., Zwahlen, R., Weber, F.E., Molenberg, A., van Lenthe, G.H. and Hammerle, C.H.F. Evaluation of an in situ formed synthetic hydrogel as a biodegradable membrane for guided bone regeneration. *Clinical Oral Implants Research*. 2006. 17(4): 426-433.
44. Nieminen, T., Kallela, I., Keränen, J., Hiidenheimo, I., Kainulainen, H., Wuolijoki, E. and Rantala, I. In vivo and in vitro degradation of a novel

- bioactive guided tissue regeneration membrane. *International Journal of Oral and Maxillofacial Surgery*. 2006. 35(8): 727-732.
45. Schliephake, H., Dard, M., Planck, H., Hierlemann, H. and Jakob, A. Guided bone regeneration around endosseous implants using a resorbable membrane vs a PTFE membrane. *Clinical oral implants research*. 2000. 11(3): 230-41.
 46. Bottino, M.C., Kamocki, K., Yassen, G.H., Platt, J.A., Vail, M.M., Ehrlich, Y., Spolnik, K.J. and Gregory, R.L. Bioactive Nanofibrous Scaffolds for Regenerative Endodontics. *Journal of Dental Research*. 2013. 92(11): 963-969.
 47. Vasconcelos, M., Afonso, A., Branco, R. and Cavalheiro, J. Guided bone regeneration using osteopatite granules and polytetrafluoroethylene membranes. *Journal of Materials Science: Materials in Medicine*. 1997. 8: 815-818.
 48. Hitti, R.A. and Kerns, D.G. Guided Bone Regeneration in the Oral Cavity : A Review. *Pathology*. 2011. 5: 33-45.
 49. Ten Heggeler, J.M.A.G., Slot, D.E. and Van der Weijden, G.A. Effect of socket preservation therapies following tooth extraction in non-molar regions in humans: a systematic review. *Clinical Oral Implants Research*. 2011. 22(8): 779-788.
 50. Pilipchuk, S.P., Plonka, A.B., Monje, A., Taut, A.D., Lanis, A., Kang, B. and Giannobile, W.V. Tissue engineering for bone regeneration and osseointegration in the oral cavity. *Dental Materials*. 2015. 31(4): 317-338.
 51. De Boever, A.L. and De Boever, J.A. Guided bone regeneration around non-submerged implants in narrow alveolar ridges: a prospective long-term clinical study. *Clinical Oral Implants Research*. 2005. 16(5): 549-556.
 52. Rakhmatia, Y.D., Ayukawa, Y., Furuhashi, A. and Koyano, K. Current barrier membranes: Titanium mesh and other membranes for guided bone regeneration in dental applications. *Journal of Prosthodontic Research*. 2013. 57(1): 3-14.
 53. Retzepi, M. and Donos, N. Guided Bone Regeneration: biological principle and therapeutic applications. *Clinical Oral Implants Research*. 2010. 21(6): 567-576.
 54. Hämmerle, C.H.F. and Jung, R.E. Bone augmentation by means of barrier membranes. *Periodontology 2000*. 2003. 33: 36-53.

55. Dumitrescu, A.L. Guided Tissue Regeneration Barriers. 2011. 1-71.
56. Moses, O., Pitaru, S., Artzi, Z. and Nemcovsky, C.E. Healing of dehiscence-type defects in implants placed together with different barrier membranes: a comparative clinical study. *Clinical Oral Implants Research*. 2005. 16(2): 210-219.
57. Kim, Y.-K., Yun, P.-Y., Kim, S.-G. and Oh, D.S. In vitro scanning electron microscopic comparison of inner surface of exposed and unexposed nonresorbable membranes. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*. 2009. 107(6): e5-e11.
58. Strietzel, F.P., Khongkhunthian, P., Khattiya, R., Patchanee, P. and Reichart, P.A. Healing Pattern of Bone Defects Covered by Different Membrane Types — A Histologic Study in the Porcine Mandible. *Journal of Biomedical Materials Research Part B: Applied Biomaterials*. 2005. 35-46.
59. Donos, N., Kostopoulos, L. and Karring, T. Alveolar ridge augmentation using a resorbable copolymer membrane and autogenous bone grafts. An experimental study in the rat. *Clinical oral implants research*. 2002. 13(2): 203-213.
60. Belleggia, F. Treatment of an infected exposure of a dense polytetrafluoroethylene membrane in a vertical guided bone regeneration procedure : a protocol proposal. *Clinical Oral Implants Research*. 2014. 25 (Suppl. 10).
61. Harzeler, M.R., Kohal, R.J., Naghshbandi, J., Mota, L.F., Conradt, J., Mote, L.F. and Conradt, J. Evaluation of a new bioresorbable barrier to facilitate guided bone regeneration around exposed implant threads An experimental study in the monkey. *Int. J. Oral Maxillofacial Surgery*. 1998. 27: 315-320.
62. Coelho, P.G., Giro, G., Kim, W., Granato, R., Marin, C., Bonfante, E.A., Bonfante, S., Lilin, T. and Suzuki, M. Evaluation of collagen-based membranes for guided bone regeneration, by three-dimensional computerized microtomography. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*. 2012. 114(4): 437-443.
63. Gentile, P., Chiono, V., Tonda-Turo, C., Ferreira, A.M. and Ciardelli, G. Polymeric membranes for guided bone regeneration. *Biotechnology Journal*. 2011. 6(10): 1187-1197.

64. Song, J.-h., Kim, H.-e. and Kim, H.-w. Collagen-Apatite Nanocomposite Membranes for Guided Bone Regeneration. *Journal of Biomedical Materials Research*. 2007. 248-257.
65. Landi, E., Tampieri, A., Mattioli-Belmonte, M., Celotti, G., Sandri, M., Gigante, A., Fava, P. and Biagini, G. Biomimetic Mg- and Mg₂CO₃-substituted hydroxyapatites: synthesis characterization and in vitro behaviour. *Journal of the European Ceramic Society*. 2006. 26(13): 2593-2601.
66. Zhou, H. and Lee, J. Nanoscale hydroxyapatite particles for bone tissue engineering. *Acta Biomaterialia*. 2011. 7(7): 2769-2781.
67. Park, J.K., Yeom, J., Oh, E.J., Reddy, M., Kim, J.Y., Cho, D.-W., Lim, H.P., Kim, N.S., Park, S.W., Shin, H.-I., Yang, D.J., Park, K.B. and Hahn, S.K. Guided bone regeneration by poly(lactic-co-glycolic acid) grafted hyaluronic acid bi-layer films for periodontal barrier applications. *Acta Biomaterialia*. 2009. 5(9): 3394-3403.
68. Parent, M., Nouvel, C., Koerber, M., Sapin, A., Maincent, P. and Boudier, A. PLGA in situ implants formed by phase inversion: Critical physicochemical parameters to modulate drug release. *Journal of Controlled Release*. 2013. 172(1): 292-304.
69. Rezwan, K., Chen, Q.Z., Blaker, J.J. and Boccaccini, A.R. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. *Biomaterials*. 2006. 27(18): 3413-3431.
70. Budyanto, L., Goh, Y.Q. and Ooi, C.P. Fabrication of porous poly(L-lactide) (PLLA) scaffolds for tissue engineering using liquid-liquid phase separation and freeze extraction. *Journal of Materials Science: Materials in Medicine*. 2008. 20(1): 105-111.
71. Zamani, M., Morshed, M., Varshosaz, J. and Jannesari, M. Controlled release of metronidazole benzoate from poly ϵ -caprolactone electrospun nanofibers for periodontal diseases. *European Journal of Pharmaceutics and Biopharmaceutics*. 2010. 75(2): 179-185.
72. Chen, S., Hao, Y., Cui, W., Chang, J. and Zhou, Y. Biodegradable electrospun PLLA/chitosan membrane as guided tissue regeneration membrane for treating periodontitis. *Journal of Materials Science*. 2013. 48(19): 6567-6577.

73. Ranjbar-Mohammadi, M., Zamani, M., Prabhakaran, M.P., Bahrami, S.H. and Ramakrishna, S. Electrospinning of PLGA/gum tragacanth nanofibers containing tetracycline hydrochloride for periodontal regeneration. *Materials Science and Engineering: C*. 2016. 58: 521-531.
74. Yüksel, E., Karakeçili, A., Demirtaş, T.T. and Gümüşderelioğlu, M. Preparation of bioactive and antimicrobial PLGA membranes by magainin II/EGF functionalization. *International Journal of Biological Macromolecules*. 2016. 86: 162-168.
75. Dorozhkin, S.V. Nanosized and nanocrystalline calcium orthophosphates. *Acta Biomaterialia*. 2010. 6(3): 715-734.
76. Laurencin, D., Almora-Barrios, N., de Leeuw, N.H., Gervais, C., Bonhomme, C., Mauri, F., Chrzanowski, W., Knowles, J.C., Newport, R.J., Wong, A., Gan, Z. and Smith, M.E. Magnesium incorporation into hydroxyapatite. *Biomaterials*. 2011. 32(7): 1826-1837.
77. Kannan, S., Ventura, J.M.G. and Ferreira, J.M.F. Synthesis and thermal stability of potassium substituted hydroxyapatites and hydroxyapatite/ β -tricalciumphosphate mixtures. *Ceramics International*. 2007. 33(8): 1489-1494.
78. Kothapalli, C., Wei, M., Vasiliev, A. and Shaw, M.T. Influence of temperature and concentration on the sintering behavior and mechanical properties of hydroxyapatite. *Acta Materialia*. 2004. 52(19): 5655-5663.
79. Pretto, M., Costa, A.L., Landi, E., Tampieri, A., Galassi, C. Dispersing Behavior of Hydroxyapatite Powders Produced by Wet-Chemical Synthesis. *J. Am. Ceram. Soc.* 2003. 86(9): 1534-39.
80. Kannan, S., Vieira, S.I., Olhero, S.M., Torres, P.M.C., Pina, S., da Cruz e Silva, O.A.B. and Ferreira, J.M.F. Synthesis, mechanical and biological characterization of ionic doped carbonated hydroxyapatite/ β -tricalcium phosphate mixtures. *Acta Biomaterialia*. 2011. 7(4): 1835-1843.
81. Kim, S.R., Lee, J.H., Kim, Y.T., Riu, D.H., Jung, S.J., Lee, Y.J., Chung, S.C. and Kim, Y.H. Synthesis of Si, Mg substituted hydroxyapatites and their sintering behaviors. *Biomaterials*. 2003. 24(8): 1389-98.
82. Sprio, S., Tampieri, A., Landi, E., Sandri, M., Martorana, S., Celotti, G. and Logroscino, G. Physico-chemical properties and solubility behaviour of

- multi-substituted hydroxyapatite powders containing silicon. *Materials Science and Engineering: C*. 2008. 28(1): 179-187.
83. Landi, E., Tampieri, A., Celotti, G., Sprio, S., Sandri, M. and Logroscino, G. Sr-substituted hydroxyapatites for osteoporotic bone replacement. *Acta Biomaterialia*. 2007. 3(6): 961-969.
84. Ramesh, S., Tan, C.Y., Tolouei, R., Amiriyan, M., Purbolaksono, J., Sopyan, I. and Teng, W.D. Sintering behavior of hydroxyapatite prepared from different routes. *Materials & Design*. 2012. 34: 148-154.
85. Sopyan, I., Ramesh, S. and Hamdi, M. Synthesis of nano sized hydroxyapatite powder using sol-gel technique and its conversion to dense and porous bodies. *Indian Journal of Chemistry*. 2008. 47(November): 1626-1631.
86. Landi, E., Tampieri, A., Celotti, G. and Sprio, S. Densification behaviour and mechanisms of synthetic hydroxyapatites. *J. Euro. Ceram. Soc.* 2000. 20: 2377-2387.
87. Uskoković, V. and Uskoković, D.P. Nanosized hydroxyapatite and other calcium phosphates: Chemistry of formation and application as drug and gene delivery agents. *Journal of Biomedical Materials Research Part B: Applied Biomaterials*. 2011. 96B(1): 152-191.
88. Kuriakose, T.A., Kalkura, S.N., Palanichamy, M., Arivuoli, D., Dierks, K., Bocelli, G. and Betzel, C. Synthesis of stoichiometric nano crystalline hydroxyapatite by ethanol-based sol-gel technique at low temperature. *Journal of Crystal Growth*. 2004. 263(1-4): 517-523.
89. Pang, Y.X. and Bao, X. Influence of temperature, ripening time and calcination on the morphology and crystallinity of hydroxyapatite nanoparticles. *Journal of the European Ceramic Society*. 2003. 23(10): 1697-1704.
90. Cacciotti, I., Bianco, A., Lombardi, M. and Montanaro, L. Mg-substituted hydroxyapatite nanopowders: Synthesis, thermal stability and sintering behaviour. *Journal of the European Ceramic Society*. 2009. 29(14): 2969-2978.
91. Boanini, E., Gazzano, M. and Bigi, A. Ionic substitutions in calcium phosphates synthesized at low temperature. *Acta Biomaterialia*. 2010. 6(6): 1882-1894.

92. Lazic, S., Zec, S., Miljevic, N. and Milonjic, S. The effect of temperature on the properties of hydroxyapatite precipitated from calcium hydroxide and phosphoric acid. *Thermochimica acta*. 2001. 374: 13-22.
93. Reise, M., Wyrwa, R., Müller, U., Zylinski, M., Völpel, A., Schnabelrauch, M., Berg, A., Jandt, K.D., Watts, D.C. and Sigusch, B.W. Release of metronidazole from electrospun poly(l-lactide-co-d/l-lactide) fibers for local periodontitis treatment. *Dental Materials*. 2012. 28(2): 179-188.
94. Xue, J., He, M., Niu, Y., Liu, H., Crawford, A., Coates, P., Chen, D., Shi, R. and Zhang, L. Preparation and in vivo efficient anti-infection property of GTR/GBR implant made by metronidazole loaded electrospun polycaprolactone nanofiber membrane. *International Journal of Pharmaceutics*. 2014. 475(1-2): 566-577.
95. Sundararaj, S.C., Thomas, M.V., Peyyala, R., Dziubla, T.D. and Puleo, D.A. Design of a multiple drug delivery system directed at periodontitis. *Biomaterials*. 2013. 34(34): 8835-8842.
96. Lan, S.-F., Kehinde, T., Zhang, X., Khajotia, S., Schmidtke, D.W. and Starly, B. Controlled release of metronidazole from composite poly-ε-caprolactone/alginate (PCL/alginate) rings for dental implants. *Dental Materials*. 2013. 29(6): 656-665.
97. Kitahara, T., Aoyama, Y., Hirakata, Y., Kamihira, S., Kohno, S., Ichikawa, N., Nakashima, M., Sasaki, H. and Higuchi, S. In vitro activity of lauric acid or myristylamine in combination with six antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA). *International Journal of Antimicrobial Agents*. 2006. 27(1): 51-57.
98. Pragati, S., Ashok, S. and Kuldeep, S. Recent advances in periodontal drug delivery systems. *International Journal of Drug Delivery*. 2009. 1: 1-14.
99. Castillo, A., Liebana, J., Lopez, E., Baca, P., Liebana, M. and Castillo, F. Interference of antibiotics in the growth curves of oral streptococci. *International Journal of Antimicrobial Agents*. 2006. 27(3): 263-266.
100. Pornpattananangkul, D., Fu, V., Thamphiwatana, S., Zhang, L., Chen, M., Vecchio, J., Gao, W., Huang, C.-M. and Zhang, L. In Vivo Treatment of Propionibacterium acnes Infection with Liposomal Lauric Acids. *Advanced Healthcare Materials*. 2013. 2(10): 1322-1328.

101. Huang, C.B., Alimova, Y., Myers, T.M. and Ebersole, J.L. Short- and medium-chain fatty acids exhibit antimicrobial activity for oral microorganisms. *Archives of Oral Biology*. 2011. 56(7): 650-654.
102. Kitahara, T., Koyama, N., Matsuda, J., Aoyama, Y., Hirakata, Y., Kamihira, S., Kohno, S., Nakashima, M. and Sasaki, H. Antimicrobial activity of saturated fatty acids and fatty amines against methicillin-resistant *Staphylococcus aureus*. *Biological & pharmaceutical bulletin*. 2004. 27(9): 1321-1326.
103. Amet, Y., Adas, F. and Berthou, F. High performance liquid chromatography of fatty acid metabolites Improvement of sensitivity by radiometric , fluorimetric and mass spectrometric methods. *Analytica Chimica Acta*. 2002. 465: 193-198.
104. Zhao, L., Hu, Y., Xu, D. and Cai, K. Surface functionalization of titanium substrates with chitosan–lauric acid conjugate to enhance osteoblasts functions and inhibit bacteria adhesion. *Colloids and Surfaces B: Biointerfaces*. 2014. 119: 115-125.
105. Renouf-Glauser, A.C., Rose, J., Farrar, D. and Cameron, R.E. A degradation study of PLLA containing lauric acid. *Biomaterials*. 2005. 26(15): 2415-2422.
106. Teng, S.-H., Lee, E.-J., Wang, P., Shin, D.-S. and Kim, H.-E. Three-layered membranes of collagen/hydroxyapatite and chitosan for guided bone regeneration. *Journal of Biomedical Materials Research Part B: Applied Biomaterials*. 2008. 87B(1): 132-138.
107. Vaquette, C., Frochot, C., Rahouadj, R. and Wang, X. An innovative method to obtain porous PLLA scaffolds with highly spherical and interconnected pores. *Journal of Biomedical Materials Research Part B: Applied Biomaterials*. 2008. 86B(1): 9-17.
108. Vaquette, C. and Cooper-White, J.J. Increasing electrospun scaffold pore size with tailored collectors for improved cell penetration. *Acta Biomaterialia*. 2011. 7(6): 2544-2557.
109. Ji, C., Khademhosseini, A. and Dehghani, F. Enhancing cell penetration and proliferation in chitosan hydrogels for tissue engineering applications. *Biomaterials*. 2011. 32(36): 9719-9729.

110. Cho, W.J., Kim, J.H., Oh, S.H., Nam, H.H., Kim, J.M. and Lee, J.H. Hydrophilized polycaprolactone nanofiber mesh-embedded poly(glycolic-co-lactic acid) membrane for effective guided bone regeneration. *Journal of Biomedical Materials Research Part A*. 2009. 91A(2): 400-407.
111. Teng, S.-H., Lee, E.-J., Yoon, B.-H., Shin, D.-S., Kim, H.-E. and Oh, J.-S. Chitosan/nanohydroxyapatite composite membranes via dynamic filtration for guided bone regeneration. *Journal of Biomedical Materials Research Part A*. 2009. 88A(3): 569-580.
112. Sun, F., Lim, B.-K., Ryu, S.-C., Lee, D. and Lee, J. Preparation of multi-layered film of hydroxyapatite and chitosan. *Materials Science and Engineering: C*. 2010. 30(6): 789-794.
113. Yang, Y., Zhao, J., Zhao, Y., Wen, L., Yuan, X. and Fan, Y. Formation of porous PLGA scaffolds by a combining method of thermally induced phase separation and porogen leaching. *Journal of Applied Polymer Science*. 2008. 109(2): 1232-1241.
114. Ho, M.-H., Kuo, P.-Y., Hsieh, H.-J., Hsien, T.-Y., Hou, L.-T., Lai, J.-Y. and Wang, D.-M. Preparation of porous scaffolds by using freeze-extraction and freeze-gelation methods. *Biomaterials*. 2004. 25(1): 129-138.
115. Mu, C., Su, Y., Sun, M., Chen, W. and Jiang, Z. Fabrication of microporous membranes by a feasible freeze method. *Journal of Membrane Science*. 2010. 361(1-2): 15-21.
116. Wu, L. and Ding, J. In vitro degradation of three-dimensional porous poly(d,l-lactide-co-glycolide) scaffolds for tissue engineering. *Biomaterials*. 2004. 25(27): 5821-5830.
117. Orava, E., Korventausta, J., Rosenberg, M., Jokinen, M. and Rosling, A. In vitro degradation of porous poly(dl-lactide-co-glycolide) (PLGA)/bioactive glass composite foams with a polar structure. *Polymer Degradation and Stability*. 2007. 92(1): 14-23.
118. Deb, S., Braden, M. and Bonfield, W. Water absorption characteristics of modified hydroxyapatite bone cements. *Biomaterials*. 1995. 16: 1095-1100.
119. Tang, C.Y., Chen, D.Z., Yue, T.M., Chan, K.C., Tsui, C.P. and Yu, P.H.F. Water absorption and solubility of PHBV/HA nanocomposites. *Composites Science and Technology*. 2008. 68(7-8): 1927-1934.

120. Yang, Y., Zhao, Y., Tang, G., Li, H., Yuan, X. and Fan, Y. In vitro degradation of porous poly(l-lactide-co-glycolide)/ β -tricalcium phosphate (PLGA/ β -TCP) scaffolds under dynamic and static conditions. *Polymer Degradation and Stability*. 2008. 93(10): 1838-1845.
121. Dorati, R., Colonna, C., Genta, I., Modena, T. and Conti, B. Effect of porogen on the physico-chemical properties and degradation performance of PLGA scaffolds. *Polymer Degradation and Stability*. 2010. 95(4): 694-701.
122. Fredenberg, S., Wahlgren, M., Reslow, M. and Axelsson, A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review. *International Journal of Pharmaceutics*. 2011. 415(1-2): 34-52.
123. Stevanović, M., Bračko, I., Milenković, M., Filipović, N., Nunić, J., Filipič, M. and Uskoković, D.P. Multifunctional PLGA particles containing poly(l-glutamic acid)-capped silver nanoparticles and ascorbic acid with simultaneous antioxidative and prolonged antimicrobial activity. *Acta Biomaterialia*. 2014. 10(1): 151-162.
124. Said, S.S., Aloufy, A.K., El-Halfawy, O.M., Boraie, N.A. and El-Khordagui, L.K. Antimicrobial PLGA ultrafine fibers: Interaction with wound bacteria. *European Journal of Pharmaceutics and Biopharmaceutics*. 2011. 79(1): 108-118.
125. Woodruff, M.A. and Hutmacher, D.W. The return of a forgotten polymer—Polycaprolactone in the 21st century. *Progress in Polymer Science*. 2010. 35(10): 1217-1256.
126. Ma, D. and McHugh, A.J. The interplay of membrane formation and drug release in solution-cast films of polylactide polymers. *International Journal of Pharmaceutics*. 2010. 388(1-2): 1-12.
127. Machín, R., Isasi, J.R. and Vélaz, I. Hydrogel matrices containing single and mixed natural cyclodextrins. Mechanisms of drug release. *European Polymer Journal*. 2013. 49(12): 3912-3920.
128. Wei, Z., Wang, C., Liu, H., Zou, S. and Tong, Z. Facile fabrication of biocompatible PLGA drug-carrying microspheres by O/W pickering emulsions. *Colloids and Surfaces B: Biointerfaces*. 2012. 91: 97-105.

129. Lao, L.L., Peppas, N.A., Boey, F.Y.C. and Venkatraman, S.S. Modeling of drug release from bulk-degrading polymers. *International Journal of Pharmaceutics*. 2011. 418(1): 28-41.
130. Peppas, N.A. and Narasimhan, B. Mathematical models in drug delivery: How modeling has shaped the way we design new drug delivery systems. *Journal of Controlled Release*. 2014. 190: 75-81.
131. Chou, A.H.K., LeGeros, R.Z., Chen, Z. and Li, Y. Antibacterial Effect of Zinc Phosphate Mineralized Guided Bone Regeneration Membranes. *Implant Dentistry*. 2007. 16(1): 89-100.
132. Nerem, R. Principles of tissue engineering. In: R.L. RP Lanza, J Vancanti. ed. *The Challenge of Imitating Nature*. San Diego: Academic Press. 9-11; 2000.
133. Zhang, M. Biomaterials and Tissue engineering. In: D. Shi. ed. *Biocompatibility of materials*. Heidelberg: Springer. 83-143; 2004.
134. Franks, K., Salih, V., Knowles, J. and Olsen, I. The effect of MgO on the solubility behavior and cell proliferation in a quaternary soluble phosphate based glass system. *Journal of Materials Science: Materials in Medicine*. 2002. 13: 549-556.
135. Marques, A., Reis, R. and Hunt, J. The biocompatibility of novel starch-based polymers and composites: in vitro studies. *Biomaterials*. 2002. 23: 1471-1478.
136. Renouf-Glauser, A.C., Rose, J., Farrar, D.F. and Cameron, R.E. Comparison of the hydrolytic degradation and deformation properties of a PLLA-lauric acid based family of biomaterials. *Biomacromolecules*. 2006. 7(2): 612-617.
137. Li, Z.Y., Lam, W.M., Yang, C., Xu, B., Ni, G.X., Abbah, S.A., Cheung, K.M.C., Luk, K.D.K. and Lu, W.W. Chemical composition, crystal size and lattice structural changes after incorporation of strontium into biomimetic apatite. *Biomaterials*. 2007. 28(7): 1452-1460.
138. Lima, I.R.D., Alves, G.G., Soriano, C.A., Campaneli, A.P., Gasparoto, T.H., Schnaider, E., Junior, R. and Sena, D. Understanding the impact of divalent cation substitution on hydroxyapatite: An in vitro multiparametric study on biocompatibility. *Journal of Biomedical Materials Research Part A*. 2011. 351-358.
139. Bottino, M.C., Coelho, P.G., Henriques, V.A.R., Higa, O.Z., Bressiani, A.H.A. and Bressiani, J.C. Processing, characterization, and in vitro/in vivo

- evaluations of powder metallurgy processed Ti-13Nb-13Zr alloys. *Journal of Biomedical Materials Research Part A*. 2009. 88(3): 689-696.
140. Stevanović, M.M., Škapin, S.D., Bračko, I., Milenković, M., Petković, J., Filipič, M. and Uskoković, D.P. Poly(lactide-co-glycolide)/silver nanoparticles: Synthesis, characterization, antimicrobial activity, cytotoxicity assessment and ROS-inducing potential. *Polymer*. 2012. 53(14): 2818-2828.
141. Tripathi, G., Gough, J.E., Dinda, A. and Basu, B. In vitro cytotoxicity and in vivo osseointegration properties of compression-molded HDPE-HA-Al₂O₃ hybrid biocomposites. *J Biomed Mater Res Part A*. 2013. 101A: 1539-1549.
142. Bonnier, F., Keating, M.E., Wróbel, T.P., Majzner, K., Baranska, M., Garcia-munoz, A. and Blanco, A. Toxicology in Vitro Cell viability assessment using the Alamar blue assay: A comparison of 2D and 3D cell culture models. *Toxicology In Vitro*. 2015. 29(1): 124-131.
143. Akiko Watabe, Y., Yamaguchi, T., Kawanishi, T. and Uchida, E. Target-cell specificity of fusogenic liposomes: Membrane fusion-mediated macromolecule delivery into human blood mononuclear cells. *Biochimica et Biophysica Acta*. 1999. 1416: 339-348.
144. International Standard Organisation. *Tests for cytotoxicity: in vitro methods*. Switzerland, ISO-10993-5. 2009.
145. Coecke, S., Balls, M., Bowe, G., Davis, J., Cstraunthaler, G., Hartung, T., Hay, R., Merten, O., Price, A., Schectman, L., Stacey, G. and Stokes, W. Guidance on Good Cell Culture Practice, A Report of the Second ECVAM Task Force on Good Cell Culture Practice, *ATLA*. 2005. 33: 261-287.
146. Fentem, J., Curren, R., Liebsch, M. Guidance Document on Using In vitro Data to Estimate In vivo Starting Doses for Acute Toxicity. NIH Publication No. 01-4500. August 2001.
147. American Type Culture Collection (ATCC). *American Type Culture Collection Animal Cell Culture Guide (tips and techniques for continuous cell lines)*. U.S. 2014.
148. Cadena-herrera, D., Lara, J.E.E.-d., Ramírez-ibañez, N.D., López-morales, C.A., Pérez, N.O., Flores-ortiz, L.F. and Medina-rivero, E. Validation of three viable-cell counting methods: Manual, semi-automated, and automated. *Biotechnology Reports*. 2015. 7: 9-16.

149. K.S. Louis, A.C.S., G.A. Levy. Comparison of manual versus automated trypan blue dye exclusion method for cell counting. In: Stoddart, M.J. ed. *Mammalian cell viability: Methods and Protocols, Methods in Molecular Biology*, New York: Springer Protocols. 7-12; 2015.
150. International Standard Organisation. *Biological Evaluation of Medical Devices—Part 12: Sample Preparation and Reference Materials*. Switzerland, ISO-10993-12. 2002.
151. Dygai, A.M., Ogorodova, L.M., Psakhie, S.G., Belsky, Y.P., Belska, N.V., Danilets, M.G., Ligatcheva, A.A. and Churin, A.A. A study of the Cytotoxicity of a New Nonwoven Polymeric Fibrous Bandaging Material in Vitro. *Journal of Biomaterials and Nanobiotechnology*. 2011. 2(July): 234-238.
152. Tavares, D.D.S., Castro, L.D.O., Soares, G.D.D.A., Alves, G.G. and Granjeiro, J.M. Synthesis and cytotoxicity evaluation of granular magnesium substituted β -tricalcium phosphate. *Journal of Applied Oral Science*. 2013. 21(1): 37-42.
153. Tomida, M., Nakano, K., Matsuura, S. and Kawakami, T. Comparative examination of subcutaneous tissue reaction to high molecular materials in medical use. *European Journal of Medical Research*. 2011. 16: 249-252.
154. Dimitrievska, S., Petit, A., Ajji, A., Bureau, M.N., Yahia, L.H. and Montre, P.D. Biocompatibility of novel polymer-apatite nanocomposite fibers. *Journal of Biomedical Materials Research Part A*. 2008. 84A(1): 44-53.
155. Wang, B.L.-s., Chow, P.-y., Phan, T.-t., Lim, I.J. and Yang, Y.-y. Fabrication and Characterization of Nanostructured and Thermosensitive Polymer Membranes for Wound Healing and Cell Grafting. *Adv. Funct. Mater.* 2006. 16: 1171-1178.
156. Xue, M., Hu, H., Jiang, Y., Liu, J., He, H. and Ye, X. Biodegradable polymer-coated, gelatin hydrogel/bioceramics ternary composites for antitubercular drug delivery and tissue regeneration. *Journal of Nanomaterials*. 2012. (Volume 2012): Article ID 530978.
157. Fisher, *Material Safety Data Sheet of Dimethyl Sulfoxide*. UK: 2012.
158. American Society for Testing and Materials. *Standard Test Method for in vitro Degradation Testing of Hydrolytically Degradable Polymer Resins and Fabricated Forms for Surgical Implants*. U.S., F1635-11. 2011.

159. Durect LACTEL Absorbable Polymers. *Material Safety Data Sheet of Poly(lactic-co-glycolic) acid*. U.S.:2012.
160. Loo, S.C.J., Tan, Z.Y.S., Chow, Y.J. and Lin, S.L.I. Drug Release From Irradiated PLGA and PLLA Multi-Layered Films. *Journal of pharmaceutical sciences*. 2010. 99(7): 3060-3071.
161. Mehta, A., Oeser, a.M. and Carlson, M.G. Rapid quantitation of free fatty acids in human plasma by high-performance liquid chromatography. *Journal of chromatography. B, Biomedical sciences and applications*. 1998. 719(1-2): 9-23.
162. Jaidev, L.R., Krishnan, U.M. and Sethuraman, S. Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy. *Materials Science and Engineering: C*. 2015. 47: 40-47.
163. Simchi, A., Tamjid, E., Pishbin, F. and Boccaccini, A.R. Recent progress in inorganic and composite coatings with bactericidal capability for orthopaedic applications. *Nanomedicine: Nanotechnology, Biology, and Medicine*. 2011. 7(1): 22-39.
164. Raphel, J., Holodniy, M., Goodman, S.B. and Heilshorn, S.C. Multifunctional Coatings to Simultaneously Promote Osseointegration and Prevent Infection of Orthopaedic Implants. *Biomaterials*. 2016. 84: 301-314.
165. Hoben, H.J. and Somasegaran, P. Comparison of the Pour, Spread and Drop plate methods for enumeration of Rhizobium spp. in inoculants made from presterilized peat. *Applied and Environmental Microbiology*. 1982. 44(5): 1246-1247.
166. Miles, A. A. and Misra, S.S. The estimation of the bactericidal power of blood. *Journal of Hygiene*. 1938. 38: 732-749.
167. American Society for Testing and Materials. *Determining the activity of Incorporated Antimicrobial Agent(s) In Polymeric or Hydrophobic Materials*. U.S., E2180-07. 2012.
168. Braghirolli, D.I., Steffens, D., Quintiliano, K., Acasigua, G.A.X., Gamba, D., Fleck, R.A., Petzhold, C.L. and Pranke, P. The effect of sterilization methods on electrospon poly(lactide-co-glycolide) and subsequent adhesion efficiency of mesenchymal stem cells. *Journal of Biomedical Materials Research - Part B Applied Biomaterials*. 2014. 102(4).

169. Cañadas, C., Alvarado, H., Calpena, A.C., Silva, A.M., Souto, E.B., García, M.L. and Abrego, G. In vitro , ex vivo and in vivo characterization of PLGA nanoparticles loading pranoprofen for ocular administration. *International Journal of Pharmaceutics*. 2016. 511: 719-727.
170. Rameshbabu, N., Sampath Kumar, T.S., Prabhakar, T.G., Sastry, V.S., Murty, K.V.G.K. and Prasad Rao, K. Antibacterial nanosized silver substituted hydroxyapatite: Synthesis and characterization. *Journal of Biomedical Materials Research Part A*. 2007. 80A(3): 581-591.
171. Panda, R.N., Hsieh, M.F., Chung, R.J. and Chin, T.S. FTIR , XRD , SEM and solid state NMR investigations of synthesized by hydroxide-gel technique. *Journal of Physics and Chemistry of Solids*. 2003. 64: 193-199.
172. Bogdanoviciene, I., Beganskiene, A., Tönsuaadu, K., Glaser, J., Meyer, H.J. and Kareiva, A. Calcium hydroxyapatite, $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ ceramics prepared by aqueous sol-gel processing. *Materials Research Bulletin*. 2006. 41(9): 1754-1762.
173. Costescu, A., Pasuk, I., Ungureanu, F., Dinischiotu, A., Huneau, F., Galaup, S., Coustumer, P.L.E., Predoi, D. and Ftir, C. Physico-chemical properties of nano-sized hexagonal hydroxyapatite powder synthesised by sol-gel. *Journal of Nanomaterials*. 2010. 5(4): 989-1000.
174. Landi, E., Tampieri, A., Celotti, G., Vichi, L. and Sandri, M. Influence of synthesis and sintering parameters on the characteristics of carbonate apatite. *Biomaterials*. 2004. 25(10): 1763-1770.
175. Greish, Y.E., Sturgeon, J.L., Singh, A., Krogman, N.R., Touny, A.H., Sethuraman, S., Nair, L.S., Laurencin, C.T., Allcock, H.R. and Brown, P.W. Formation and properties of composites comprised of calcium-deficient hydroxyapatites and ethyl alanate polyphosphazenes. *Journal of Materials Science: Materials in Medicine*. 2008. 19(9): 3153-3160.
176. Gustavsson, J., Ginebra, M.P., Engel, E. and Planell, J. Ion reactivity of calcium-deficient hydroxyapatite in standard cell culture media. *Acta Biomaterialia*. 2011. 7(12): 4242-4252.
177. Koutsopoulos, S. Synthesis and characterization of hydroxyapatite crystals: a review study on the analytical methods. *Journal of Biomedical Materials Research Part A*. 2002. 62: 600-612.

178. Gibson, I.R., Ke, S., Best, S.M. and Bonfield, W. Effect of powder characteristics on the sinterability of hydroxyapatite powders. *Journal of materials science. Materials in medicine*. 2001. 12(2): 163-171.
179. Suetsugu, Y., Takahashi, Y., Okamura, F.P. and Tanaka, J. Structure analysis of A-type carbonate apatite by a single-crystal x-ray diffraction method. *Journal of Solid State Chemistry*. 2000. 155: 292-297.
180. El Feki, H., Savariault, J.M., Ben Salah, A. Structure refinements by the Rietveld method of partially substituted hydroxyapatite: $\text{Ca}_9\text{Na}_{0.5}(\text{PO}_4)_{4.5}(\text{CO}_3)_{1.5}(\text{OH})_2$. *Journal of Alloys and Compounds*. 1999. 287: 114-120.
181. Gibson, I.R. and Bonfield, W. Novel synthesis and characterization of an AB-type carbonate-substituted hydroxyapatite. *Journal of Biomedical Materials Research*. 2002. 59(4): 697-708.
182. Joschek, S., Nies, B., Krotz, R. and Göferich, A. Chemical and physicochemical characterization of porous hydroxyapatite ceramics made of natural bone. *Biomaterials*. 2000. 21(16): 1645-58.
183. Fu, X., Liu, Z., Xiao, Y., Wang, J. and Lei, J. Preparation and properties of lauric acid/diatomite composites as novel form-stable phase change materials for thermal energy storage. *Energy and Buildings*. 2015. 104: 244-249.
184. Hao, S., Wang, Y., Wang, B., Deng, J., Zhu, L. and Cao, Y. Formulation of porous poly(lactic-co-glycolic acid) microparticles by electrospray deposition method for controlled drug release. *Materials science & engineering. C, Materials for biological applications*. 2014. 39: 113-119.
185. Wei, J. and Li, Y. Tissue engineering scaffold material of nano-apatite crystals and polyamide composite. *European Polymer Journal*. 2004. 40(3): 509-515.
186. Jose, M., Thomas, V., Johnson, K., Dean, D. and Nyairo, E. Aligned PLGA/HA nanofibrous nanocomposite scaffolds for bone tissue engineering. *Acta Biomaterialia*. 2009. 5(1): 305-315.
187. Tanaka, H., Watanabe, T., Chikazawa, M., Kandori, K. and Ishikawa, T. TPD , FTIR , and Molecular Adsorption Studies of Calcium Hydroxyapatite Surface Modified with Hexanoic and Decanoic Acids. *Journal of Colloid and Interface Science*. 1999. 214: 31-37.

188. Zhou, S., Zheng, X., Yu, X., Wang, J., Weng, J., Li, X., Feng, B. and Yin, M. Hydrogen Bonding Interaction of Poly (D , L -Lactide)/ hydroxyapatite Nanocomposites. *Chemical Materials*. 2007. 19(20): 247-253.
189. Ma, S., Chen, Z., Qiao, F., Sun, Y., Yang, X., Deng, X., Cen, L., Cai, Q., Wu, M., Zhang, X. and Gao, P. Guided bone regeneration with tripolyphosphate cross-linked asymmetric chitosan membrane. *Journal of Dentistry*. 2014. 42(12): 1603-1612.
190. Cao, N., Yang, X. and Fu, Y. Effects of various plasticizers on mechanical and water vapor barrier properties of gelatin films. *Food Hydrocolloids*. 2009. 23(3): 729-735.
191. Tarvainen, M., Sutinen, R., Peltonen, S., Mikkonen, H., Maunus, J., Vähä-Heikkilä, K., Lehto, V.-P. and Paronen, P. Enhanced film-forming properties for ethyl cellulose and starch acetate using n-alkenyl succinic anhydrides as novel plasticizers. *European Journal of Pharmaceutical Sciences*. 2003. 19(5): 363-371.
192. Vieira, M.G.A., da Silva, M.A., dos Santos, L.O. and Beppu, M.M. Natural-based plasticizers and biopolymer films: A review. *European Polymer Journal*. 2011. 47(3): 254-263.
193. Duan, B., Wu, L., Yuan, X., Hu, Z., Li, X., Zhang, Y., Yao, K. and Wang, M. Hybrid nanofibrous membranes of PLGA/chitosan fabricated via an electrospinning array. *Journal of Biomedical Materials Research Part A*. 2007. 83A(3): 868-878.
194. Ebrahimian-Hosseiniabadi, M., Ashrafizadeh, F., Etemadifar, M. and Venkatraman, S.S. Preparation and mechanical behavior of PLGA/nano-BCP composite scaffolds during in-vitro degradation for bone tissue engineering. *Polymer Degradation and Stability*. 2011. 96(10): 1940-1946.
195. Lu, L., Peter, S.J., Lyman, M.D., Lai, H.-I., Leite, S.M., Tamada, J.A., Uyama, S., Vacanti, J.P., Langer, R. and Mikos, A.G. In vitro and in vivo degradation of porous poly (DL-lactic-co-glycolic acid) foams. *Biomaterials*. 2000. 21: 1837-1845.
196. Ramchandani, M., Pankaskie, M. and Robinson, D. The influence of manufacturing procedure on the degradation of poly(lactide-co-glycolide) 85:15 and 50:50 implants. *Journal of Controlled Release*. 1997. 43: 161-173.

197. Tarola, A.M., Girelli, A.M. and Lorusso, S. High Performance Liquid Chromatography Determination of Fatty Acids in Drying Oils Following Lipase Action. *Journal of Chromatographic Science*. 2012. 50(4): 294-300.
198. Ding, A.G. and Schwendeman, S.P. Determination of water-soluble acid distribution in poly(lactide-co-glycolide). *Journal of pharmaceutical sciences*. 2004. 93(2): 322-331.
199. Peppas, N.A. and Khare, A.R. Preparation , structure and diffusional behavior of hydrogels in controlled release. *Advanced Drug Delivery Reviews*. 1993. 11: 1-35.
200. Pastorino, D., Canal, C. and Ginebra, M.-P. Drug delivery from injectable calcium phosphate foams by tailoring the macroporosity–drug interaction. *Acta Biomaterialia*. 2015. 12: 250-259.
201. Zuleger, S. and Lippold, B.C. Polymer particle erosion controlling drug release . I . Factors influencing drug release and characterization of the release mechanism. *International Journal of Pharmaceutics*. 2001. 217: 139-152.
202. Matsuo, M., Oogai, Y., Kato, F., Sugai, M. and Komatsuzawa, H. Growth-phase dependence of susceptibility to antimicrobial peptides in *Staphylococcus aureus*. *Microbiology*. 2011. 157(6): 1786-1797.
203. Farokhi, M., Mottaghitalab, F., Shokrgozar, M.A., Ou, K.-L., Mao, C. and Hosseinkhani, H. Importance of dual delivery systems for bone tissue engineering. *Journal of Controlled Release*. 2016. 225: 152-169.
204. Kirkham, L.-a.S., Corscadden, K.J., Wiertsema, S.P., Currie, A.J. and Richmond, P.C. A practical method for preparation of pneumococcal and nontypeable *Haemophilus influenzae* inocula that preserves viability and immunostimulatory activity. *BMC Research Notes*. 2013. 6: 522.
205. Cells, H., Harris, L.G., Foster, S.J., Richards, R.G. and Harris, L. An introduction to *staphylococcus aureus*, and techniques for identifying and quantifying *s.aureus* adhesins in relation to adhesin to biomaterials: Review. *European Cells and Materials*. 2002. 4: 39-60.
206. Udekwu, K.I., Parrish, N., Ankomah, P., Baquero, F. and Levin, B.R. Functional relationship between bacterial cell density and the efficacy of antibiotics. *Journal of Antimicrobial Chemotherapy*. 2009. 63(4): 745-757.

207. Dayrit, F.M. The Properties of Lauric Acid and Their Significance in Coconut Oil. *Journal of the American Oil Chemists' Society*. 2014. 92(1): 1-15.
208. Fischer, C.L., Drake, D.R., Dawson, D.V., Blanchette, D.R., Brogden, K.A. and Wertz, P.W. Antibacterial Activity of Sphingoid Bases and Fatty Acids against Gram-Positive and Gram-Negative Bacteria. *Antimicrobial Agents and Chemotherapy*. 2011. 56(3): 1157-1161.
209. Umerska, A., Cassisa, V., Matougui, N., Joly-Guillou, M.-L., Eveillard, M. and Saulnier, P. Antibacterial action of lipid nanocapsules containing fatty acids or monoglycerides as co-surfactants. *European Journal of Pharmaceutics and Biopharmaceutics*. 2016. 108: 100-110.